Major Pharmaceuticals Industry Financials, Performance and Ratios
-
Industry Score
38.6 /100
Rank 49 out of 131 Industries -
Advance/Decline
72/273
-
No. of Companies345
-
Avg. Market Cap13,088
-
Price to Earning Ratio10.58
-
Price to Earning Growth Ratio1.26
-
Price to Book Ratio26.00
-
Return on Equity4.91
-
Return on Capital Employed-
-
Return on Assets3.00
-
Dividend yield 1 year %0.80 %
-
Net Profit Growth Annual YoY %5.77 %
-
Net Profit Growth Qtr YoY %93.60 %
-
Net Profit Growth Qtr QoQ %171.51 %
Show more
*All values are market cap weighted averages.
*All Financial parameters are in Million USD.
Major Pharmaceuticals Industry Market Breadth
- < -5%
- -2 to -5%
- 0 to -2%
- 0 to 2%
- 2 to 5%
- > 5%
Major Pharmaceuticals Peer comparison
Compare all stocks in Major Pharmaceuticals industry listed on stock exchanges
| Stock Name | 3M Price Chart | Market Cap | LTPLast Traded Price | Day High Low (%) | Week High Low (%) | Month High Low (%) | Qtr High Low(%) | 1 Year High low(%) | 3 Year High low(%) | 5 Year High low(%) | 10 Year High low(%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AbbVie |
|
372,659.3
|
210.8
|
L
 -4.1%
H
209.4
219
|
L
 -7.2%
H
209.4
229.3
|
L
 -9.5%
H
209.4
237.1
|
L
 -6.0%
H
204.3
237.1
|
L
 -1.7%
H
164.4
244.8
|
L
 36.7%
H
131.0
244.8
|
L
 100.6%
H
102.1
244.8
|
L
 281.0%
H
54.8
244.8
|
| Adc Therapeutics SA |
|
499.2
|
4.0
|
L
 -2.0%
H
4.0
4.1
|
L
 -16.0%
H
4.0
5.0
|
L
 -3.6%
H
3.9
5.0
|
L
 9.8%
H
3.3
5.0
|
L
 125.1%
H
1.1
5.0
|
L
 79.9%
H
0.4
6.0
|
L
 -86.3%
H
0.4
32
|
L
H
0.4
56.6
|
| Amneal Pharma Inc (Class A) |
|
3,920.3
|
12.5
|
L
 0.2%
H
12.2
12.5
|
L
 -6.7%
H
11.8
13.2
|
L
 -18.0%
H
11.8
15.2
|
L
 1.1%
H
11.8
15.4
|
L
 44.6%
H
6.7
15.4
|
L
 771.3%
H
1.2
15.4
|
L
 82.4%
H
1.2
15.4
|
L
 -61.0%
H
1.2
37.2
|
| Annovis Bio Inc |
|
66.5
|
2.5
|
L
 -8.4%
H
2.5
2.8
|
L
 -2.7%
H
2.4
3.0
|
L
 5.5%
H
2.4
3.0
|
L
 -30.7%
H
2.3
4.1
|
L
 30.1%
H
1.1
5.5
|
L
 -83.8%
H
1.1
23.9
|
L
 -93.5%
H
1.1
132
|
L
H
1.1
132
|
| Bausch Health Companies Inc |
|
1,871.3
|
5.1
|
L
 -2.5%
H
5.1
5.2
|
L
 -6.5%
H
4.9
5.5
|
L
 -15.7%
H
4.9
6.3
|
L
 -26.0%
H
4.9
8
|
L
 -28.3%
H
4.3
8.7
|
L
 -33.6%
H
4.0
11.5
|
L
 -84.8%
H
4.0
34.5
|
L
 -83.0%
H
4.0
38.5
|
| Bristol-Myers Squibb |
|
120,722.2
|
59.3
|
L
 -0.7%
H
58.8
59.7
|
L
 -1.4%
H
58.3
60.8
|
L
 -1.8%
H
58.3
62.9
|
L
 10.7%
H
52.1
62.9
|
L
 -1.2%
H
42.5
62.9
|
L
 -10.9%
H
39.4
71.1
|
L
 -4.7%
H
39.4
81.4
|
L
 -3.6%
H
39.4
81.4
|
| Emergent Biosolutions Inc |
|
417.8
|
8.1
|
L
 -0.1%
H
8.0
8.1
|
L
 -3.8%
H
8.0
8.4
|
L
 -24.6%
H
7.8
11.5
|
L
 -33.9%
H
7.8
14.1
|
L
 39.4%
H
4.0
14.1
|
L
 -0.6%
H
1.4
15.1
|
L
 -91.2%
H
1.4
96.0
|
L
 -73.0%
H
1.4
137.6
|
| GSK PLC (ADR) |
|
104,622.5
|
52.3
|
L
 -2.2%
H
51.8
52.9
|
L
 -5.5%
H
51.8
55.6
|
L
 -14.1%
H
51.8
61.7
|
L
 7.3%
H
47.6
61.7
|
L
 29.8%
H
32.4
61.7
|
L
 53.4%
H
31.7
61.7
|
L
 41.2%
H
28.5
61.7
|
L
 26.0%
H
28.5
61.7
|
| Johnson & Johnson |
|
571,676.2
|
237.2
|
L
 -0.4%
H
235.4
239.1
|
L
 -2.7%
H
235.4
245.6
|
L
 -2.5%
H
235.4
251.7
|
L
 12.8%
H
200.9
251.7
|
L
 45.7%
H
141.5
251.7
|
L
 55.7%
H
140.7
251.7
|
L
 47.6%
H
140.7
251.7
|
L
 122.2%
H
106.4
251.7
|
| Eli Lilly |
|
818,507.9
|
916.6
|
L
 -1.5%
H
905.1
929
|
L
 -8.5%
H
905.1
1003.2
|
L
 -11.5%
H
905.1
1064.5
|
L
 -12.0%
H
905.1
1134.0
|
L
 11.1%
H
623.8
1134.0
|
L
 178.4%
H
323.3
1134.0
|
L
 390.9%
H
178.6
1134.0
|
L
 1227.2%
H
64.2
1134.0
|
| Merck & Company |
|
282,050.5
|
114.1
|
L
 -1.5%
H
113.3
115.6
|
L
 -2.6%
H
113.3
117.9
|
L
 -6.2%
H
113.3
125.1
|
L
 15.0%
H
98.9
125.1
|
L
 20.4%
H
73.3
125.1
|
L
 9.6%
H
73.3
134.6
|
L
 54.7%
H
69.5
134.6
|
L
 132.0%
H
49.2
134.6
|
| Novo Nordisk (ADR) |
|
166,405.5
|
37.5
|
L
 -2.5%
H
37
37.7
|
L
 -3.2%
H
37
39.3
|
L
 -24.1%
H
35.9
49.4
|
L
 -21.6%
H
35.9
64.2
|
L
 -53.3%
H
35.9
82.6
|
L
 -46.3%
H
35.9
148.2
|
L
 4.4%
H
33.3
148.2
|
L
 35.2%
H
15.5
148.2
|
| Novartis AG (ADR) |
|
287,901.9
|
150.9
|
L
 -2.6%
H
150.1
152.8
|
L
 -3.8%
H
150.1
156.6
|
L
 -9.2%
H
150.1
170.5
|
L
 11.7%
H
134.8
170.5
|
L
 34.5%
H
97.7
170.5
|
L
 83.6%
H
82.0
170.5
|
L
 76.2%
H
74.1
170.5
|
L
 132.9%
H
59.2
170.5
|
| Organon & Co. |
|
1,619.2
|
6.2
|
L
 -2.7%
H
6.2
6.3
|
L
 -4.0%
H
6.2
6.5
|
L
 -14.6%
H
6.2
8.2
|
L
 -11.0%
H
6.2
9.9
|
L
 -60.2%
H
6.2
15.9
|
L
 -71.3%
H
6.2
24.8
|
L
H
6.2
39.5
|
L
H
6.2
39.5
|
| Prestige Consumer Healthcare Inc |
|
2,891.6
|
61.1
|
L
 -1.9%
H
61.0
62.7
|
L
 -6.6%
H
60.9
65.6
|
L
 -7.8%
H
60.9
71.1
|
L
 -1.9%
H
60.2
71.1
|
L
 -28%
H
57.3
89.4
|
L
 -0.3%
H
56.0
90.0
|
L
 31.0%
H
42.7
90.0
|
L
 17.7%
H
26.3
90.0
|
| Pfizer |
|
154,950.8
|
27.3
|
L
 -0.7%
H
26.8
27.3
|
L
 0.3%
H
26.5
27.8
|
L
 -0.4%
H
26.2
27.8
|
L
 8.8%
H
24.8
27.9
|
L
 4.7%
H
20.9
27.9
|
L
 -32.0%
H
20.9
42.2
|
L
 -23.9%
H
20.9
61.7
|
L
 -1.9%
H
20.9
61.7
|
| Perrigo Co PLC |
|
1,351.7
|
9.8
|
L
 -4.7%
H
9.7
10.2
|
L
 -2.8%
H
9.2
10.5
|
L
 -32.0%
H
9.2
15.0
|
L
 -26.5%
H
9.2
15.4
|
L
 -65.3%
H
9.2
29.1
|
L
 -71.8%
H
9.2
40.3
|
L
 -76.3%
H
9.2
50.9
|
L
 -92.5%
H
9.2
133.9
|
| Dr. Reddy`s Laboratories Ltd (ADR) |
|
11,681.3
|
14.0
|
L
 -1.1%
H
13.9
14.1
|
L
 -3.3%
H
13.9
14.5
|
L
 -2.6%
H
13.9
14.8
|
L
 0.7%
H
12.8
14.8
|
L
 6.1%
H
12.3
16.2
|
L
 27.3%
H
10.6
74.9
|
L
 17.4%
H
9.6
74.9
|
L
 50.9%
H
5.6
74.9
|
| Takeda pharma Co (ADR) |
|
57,149.8
|
18.1
|
L
 -1.6%
H
18.0
18.3
|
L
 -0.7%
H
17.7
18.5
|
L
 -0.9%
H
17.5
18.8
|
L
 25.0%
H
14.7
18.8
|
L
 19.2%
H
13.0
18.8
|
L
 10.4%
H
12.6
18.8
|
L
 -7.3%
H
12.3
20.0
|
L
 -25.4%
H
12.3
30.6
|
| Teva- pharma Ind Ltd (ADR) |
|
34,834.3
|
29.9
|
L
 -0.6%
H
29.8
30.1
|
L
 -5.1%
H
28.4
31.4
|
L
 -13.1%
H
28.4
35.2
|
L
 -0.5%
H
28.4
37.3
|
L
 79.0%
H
12.5
37.3
|
L
 257.8%
H
7.1
37.3
|
L
 155.6%
H
6.8
37.3
|
L
 -44.1%
H
6.1
58.2
|
| Zoetis (Class A) |
|
50,195.2
|
118.9
|
L
 -2.3%
H
118.6
120.8
|
L
 -1.3%
H
114.5
122.5
|
L
 -5.3%
H
114.5
132.3
|
L
 -2.7%
H
114.5
132.5
|
L
 -28.0%
H
114.5
172.2
|
L
 -27.7%
H
114.5
201.9
|
L
 -23.9%
H
114.5
249.3
|
L
 199.4%
H
39.8
249.3
|
| Biohaven Ltd |
|
1,391.4
|
9.3
|
L
 -2.9%
H
9.2
9.4
|
L
 -9.9%
H
9.2
10.9
|
L
 -19.4%
H
9.2
12.1
|
L
 -14.9%
H
9.2
14.0
|
L
 -68.8%
H
7.5
31.2
|
L
 -32.8%
H
7.5
62.2
|
L
H
5.5
62.2
|
L
H
5.5
62.2
|
| Abeona Therapeutics Inc |
|
245.5
|
4.5
|
L
 -4.8%
H
4.4
4.7
|
L
 -11.9%
H
4.4
5.1
|
L
 -10.1%
H
4.4
5.6
|
L
 -6.6%
H
4.4
5.7
|
L
 -14.5%
H
3.9
7.5
|
L
 89.5%
H
2.2
9.0
|
L
 -92.2%
H
2.2
57.2
|
L
 -93.5%
H
2.2
568.8
|
| Oruka Therapeutics Inc |
|
2,003.2
|
41.4
|
L
 0.2%
H
40.6
41.7
|
L
 22.8%
H
31.3
42.4
|
L
 26.6%
H
31.1
42.4
|
L
 45.8%
H
25.2
42.4
|
L
 248.0%
H
5.5
42.4
|
L
 61.1%
H
2.2
53.9
|
L
 -16.9%
H
2.2
53.9
|
L
 -94.9%
H
2.2
939.6
|
| Acumen Pharma Inc |
|
175.7
|
2.9
|
L
 -6.2%
H
2.9
3.1
|
L
 -13.7%
H
2.9
3.6
|
L
 18.4%
H
2.4
3.6
|
L
 41.5%
H
1.7
3.6
|
L
 126.6%
H
0.9
3.6
|
L
 -25.1%
H
0.9
11.3
|
L
H
0.9
27.0
|
L
H
0.9
27.0
|
| Arbutus Biopharma Corp |
|
823.1
|
4.3
|
L
 -1.8%
H
4.3
4.4
|
L
 -9.1%
H
4.2
4.8
|
L
 2.6%
H
4.1
4.9
|
L
 -7.8%
H
3.5
5.1
|
L
 30.5%
H
2.7
5.1
|
L
 43.1%
H
1.7
5.1
|
L
 15.4%
H
1.7
6.5
|
L
 17.6%
H
0.8
12.6
|
| ABVC BioPharma Inc |
|
32.3
|
1.3
|
L
 -4.5%
H
1.3
1.3
|
L
 -13.0%
H
1.2
1.4
|
L
 -22.1%
H
1.2
1.7
|
L
 -37.4%
H
1.2
2.5
|
L
 95.4%
H
0.7
5.5
|
L
 -78.8%
H
0.4
9.6
|
L
 -97.1%
H
0.4
299.5
|
L
 -99.9%
H
0.4
378
|
| Acadia Pharma Inc |
|
3,447.4
|
20.2
|
L
 -3.3%
H
20.1
20.8
|
L
 -10.3%
H
20.1
22.5
|
L
 -11.9%
H
20.1
25.4
|
L
 -24.9%
H
20.1
28.4
|
L
 17.6%
H
13.4
28.4
|
L
 2.1%
H
13.4
33.9
|
L
 -26.6%
H
12.2
33.9
|
L
 3.5%
H
12.2
58.7
|
| Adicet Bio Inc |
|
65.9
|
6.9
|
L
 -4.6%
H
6.8
7.1
|
L
 -8.9%
H
6.8
7.7
|
L
 -2.6%
H
6.7
8.1
|
L
 -8.8%
H
6.4
9.1
|
L
 -44.8%
H
6.4
17.4
|
L
 -94.2%
H
6.4
120.5
|
L
 -97.2%
H
6.4
349.9
|
L
H
6.4
349.9
|
| Achieve Life Sciences Inc |
|
216.7
|
4.1
|
L
 -4.2%
H
4.1
4.3
|
L
 -4.9%
H
4.1
4.4
|
L
 -4.0%
H
4.1
4.8
|
L
 -3.8%
H
3.9
6.0
|
L
 39.9%
H
1.8
6.0
|
L
 -6.4%
H
1.8
10.3
|
L
 -67.3%
H
1.8
13.0
|
L
 -99.8%
H
1.8
3123.8
|
| AC Immune SA |
|
314.9
|
3.1
|
L
 -5.7%
H
3.1
3.4
|
L
 3.0%
H
2.9
3.4
|
L
 7.6%
H
2.4
3.4
|
L
 6.5%
H
2.4
3.9
|
L
 41.6%
H
1.4
4
|
L
 41.0%
H
1.4
5.1
|
L
 -60.3%
H
1.4
12.6
|
L
H
1.4
20.0
|
| Aclaris Therapeutics Inc |
|
444.4
|
3.7
|
L
 -5.4%
H
3.7
3.9
|
L
H
3.4
3.9
|
L
 12.6%
H
2.8
3.9
|
L
 21.1%
H
2.5
4.9
|
L
 132.3%
H
1.1
4.9
|
L
 -53.5%
H
0.6
11.1
|
L
 -84.7%
H
0.6
30.4
|
L
 -77.0%
H
0.6
33.3
|
| Acrivon Therapeutics Inc |
|
51.4
|
1.6
|
L
 -1.8%
H
1.6
1.7
|
L
 -1.8%
H
1.6
1.8
|
L
 1.9%
H
1.4
1.9
|
L
 -29.4%
H
1.4
3.6
|
L
 -70.4%
H
1.1
5.7
|
L
 -91.9%
H
1.1
20.1
|
L
H
1.1
25.5
|
L
H
1.1
25.5
|
| Acelrx Pharma Inc |
|
14.2
|
0.8
|
L
 6.3%
H
0.8
0.9
|
L
 -5.6%
H
0.8
0.9
|
L
 6.3%
H
0.8
1
|
L
 -25%
H
0.8
1.3
|
L
 68%
H
0.4
1.6
|
L
 27.3%
H
0.4
1.6
|
L
 -97.8%
H
0.4
38
|
L
 -98.7%
H
0.4
115
|
| Grace Therapeutics Inc |
|
68.9
|
4.5
|
L
H
4.2
4.6
|
L
 12.7%
H
3.9
4.7
|
L
 12.9%
H
3.6
4.7
|
L
 32.8%
H
3.3
4.7
|
L
 94.3%
H
1.8
4.7
|
L
 67.9%
H
1.7
5.0
|
L
 -87.1%
H
1.7
35.7
|
L
 -94.3%
H
1.7
161.1
|
| Acurx Pharma Inc |
|
12.0
|
4.7
|
L
 -3.5%
H
4.3
5.1
|
L
 62.4%
H
3.3
6.3
|
L
 137.9%
H
1.3
6.3
|
L
 34.6%
H
1.3
6.3
|
L
 -50.2%
H
1.3
21
|
L
 -92.5%
H
1.3
176.4
|
L
H
1.3
176.4
|
L
H
1.3
176.4
|
| Adial Pharma Inc |
|
2.6
|
1.8
|
L
 -3.2%
H
1.8
1.9
|
L
H
1.8
2.0
|
L
 -32.2%
H
1.5
2.9
|
L
 -72.1%
H
1.5
6.9
|
L
 -90.0%
H
1.5
30.3
|
L
 -99.3%
H
1.5
350
|
L
 -99.9%
H
1.5
3175
|
L
H
1.5
5900
|
| Agios Pharma Inc |
|
1,654.6
|
28.2
|
L
 -2.3%
H
28.1
28.8
|
L
 -0.1%
H
27
29.5
|
L
 1.5%
H
26.8
31.0
|
L
 11.0%
H
24.2
31.0
|
L
 -11.7%
H
22.2
46
|
L
 21.4%
H
19.8
62.6
|
L
 -45.2%
H
16.8
62.6
|
L
 -21.3%
H
16.8
99.8
|
| Akebia Therapeutics Inc |
|
383.1
|
1.4
|
L
 -4.0%
H
1.4
1.5
|
L
 3.6%
H
1.3
1.6
|
L
 19.2%
H
1.1
1.6
|
L
 -11.2%
H
1.1
1.7
|
L
 -40.4%
H
1.1
4.1
|
L
 123.4%
H
0.5
4.1
|
L
 -59.6%
H
0.2
4.3
|
L
 -82.5%
H
0.2
20.3
|
| Aligos Therapeutics Inc |
|
43.4
|
7.1
|
L
 -3.3%
H
7.1
7.4
|
L
 -0.6%
H
7.1
8.1
|
L
 5.7%
H
6.3
8.1
|
L
 -33.6%
H
6.2
11.5
|
L
 -39.5%
H
3.8
13.7
|
L
 -78.6%
H
3.8
46.3
|
L
 -98.9%
H
3.8
857.8
|
L
H
3.8
937.8
|
| Alkermes PLC |
|
4,522.9
|
27.1
|
L
 -1.8%
H
27
27.5
|
L
 -2.2%
H
27
28.5
|
L
 -17.5%
H
27
33.9
|
L
 -3.2%
H
27
35.3
|
L
 -21.0%
H
25.2
36.3
|
L
 4.3%
H
22.0
36.5
|
L
 34.6%
H
18.4
36.5
|
L
 -9.5%
H
12.0
71.2
|
| Allarity Therapeutics Inc |
|
19.1
|
1.2
|
L
 -4.8%
H
1.2
1.3
|
L
 -6.3%
H
1.2
1.4
|
L
 43.4%
H
0.9
1.4
|
L
 16.7%
H
0.8
1.4
|
L
 28.0%
H
0.6
2.1
|
L
 -100.0%
H
0.1
6412
|
L
H
0.1
509600
|
L
H
0.1
509600
|
| Alnylam Pharma Inc |
|
41,993.8
|
316.6
|
L
 -1.2%
H
312.6
318.5
|
L
 -1.8%
H
309.6
327.0
|
L
 -4.8%
H
309.6
345.9
|
L
 -19.3%
H
298
427.1
|
L
 25.1%
H
205.9
495.6
|
L
 70.7%
H
142.0
495.6
|
L
 118.1%
H
117.6
495.6
|
L
 447.4%
H
31.4
495.6
|
| Rein Therapeutics Inc |
|
35.2
|
1.3
|
L
 -5.6%
H
1.3
1.4
|
L
 7.2%
H
1.2
1.5
|
L
 16.5%
H
1.1
1.5
|
L
 3.1%
H
1.0
1.6
|
L
 -34.0%
H
1.0
2.4
|
L
 -4.3%
H
1.0
7.4
|
L
 -96.1%
H
1.0
35.2
|
L
H
1.0
309.6
|
| Alzamend Neuro Inc |
|
7.1
|
1.9
|
L
H
1.8
1.9
|
L
 -13.1%
H
1.8
2.4
|
L
 12.7%
H
1.6
2.4
|
L
 -13.5%
H
1.6
2.5
|
L
 -76.9%
H
1.6
10.2
|
L
 -99.7%
H
1.6
1071.9
|
L
H
1.6
45292.5
|
L
H
1.6
45292.5
|
| Amylyx Pharma Inc |
|
1,527.6
|
13.8
|
L
 -3.3%
H
13.7
14.2
|
L
 -7.7%
H
13.6
15.3
|
L
 -2.2%
H
13.5
15.7
|
L
 16.4%
H
10.8
17.5
|
L
 268.5%
H
3.1
17.5
|
L
 -54.4%
H
1.6
32.7
|
L
H
1.6
41.9
|
L
H
1.6
41.9
|
| Amphastar Pharma Inc |
|
877.5
|
19.3
|
L
 -0.9%
H
19.1
19.5
|
L
 2.3%
H
17.0
20
|
L
 -32.0%
H
17.0
29.2
|
L
 -25.8%
H
17.0
29.5
|
L
 -30.2%
H
17.0
31.3
|
L
 -46.7%
H
17.0
67.7
|
L
 7.5%
H
16.9
67.7
|
L
 70.7%
H
11.3
67.7
|
| Annexon Inc |
|
818.3
|
5.5
|
L
 -2.1%
H
5.5
5.7
|
L
 -9.7%
H
5.4
6.3
|
L
 8.9%
H
4.8
6.3
|
L
 12.0%
H
4.5
7.2
|
L
 99.6%
H
1.3
7.2
|
L
 34.9%
H
1.3
8.4
|
L
 -82.6%
H
1.3
32.7
|
L
H
1.3
38.0
|
| Apollomics Inc (Class A) |
|
41.9
|
19.5
|
L
H
19.4
19.6
|
L
 -2.1%
H
19.4
20.5
|
L
 -3.6%
H
18.6
21.5
|
L
 29.3%
H
15.1
24.2
|
L
 144.7%
H
3.7
42.1
|
L
 -98.2%
H
0.1
4900
|
L
H
0.1
4900
|
L
H
0.1
4900
|
| Apellis Pharma Inc |
|
2,298.4
|
18.0
|
L
 -4.5%
H
17.8
18.6
|
L
 -8.5%
H
17.8
19.5
|
L
 -16.6%
H
17.8
22.8
|
L
 -28.7%
H
17.8
27.5
|
L
 -28.4%
H
16.1
30.5
|
L
 -71.5%
H
16.1
94.8
|
L
 -60.9%
H
16.1
94.8
|
L
H
11.5
94.8
|
| Aptorum Grp Ltd (Class A) |
|
6.4
|
0.8
|
L
H
0.8
0.8
|
L
H
0.8
0.8
|
L
H
0.8
0.9
|
L
 -28.2%
H
0.7
1.2
|
L
 -16.0%
H
0.7
4.5
|
L
 -67.4%
H
0.5
17.5
|
L
 -97.6%
H
0.5
35.4
|
L
H
0.5
332.8
|
| Aprea Therapeutics Inc |
|
8.5
|
0.7
|
L
 -5.1%
H
0.7
0.8
|
L
 -10.8%
H
0.7
0.8
|
L
 23.3%
H
0.6
1.0
|
L
 -18.7%
H
0.6
1.5
|
L
 -68.4%
H
0.6
2.7
|
L
 -85.7%
H
0.6
8.9
|
L
 -99.4%
H
0.6
156
|
L
H
0.6
1062.2
|
| Aquestive Therapeutics Inc |
|
491.8
|
4.0
|
L
 -2.0%
H
4.0
4.1
|
L
 -4.1%
H
4.0
4.4
|
L
 3.9%
H
3.7
4.5
|
L
 -28.4%
H
2.9
6.6
|
L
 40.9%
H
2.1
7.6
|
L
 416.7%
H
0.8
7.6
|
L
 -25.4%
H
0.6
7.6
|
L
H
0.6
20.7
|
| Arcturus Therapeutics Holdings Inc |
|
181.9
|
6.4
|
L
 0.2%
H
6.4
6.7
|
L
 -16.0%
H
6.4
7.7
|
L
 -13.5%
H
6.4
8.7
|
L
 -1.8%
H
6.0
8.7
|
L
 -54.8%
H
5.9
24.2
|
L
 -58.4%
H
5.9
45
|
L
 -87.5%
H
5.9
65
|
L
 -77.5%
H
4.1
129.7
|
| Ardelyx Inc |
|
1,393.0
|
5.7
|
L
 -2.6%
H
5.7
5.8
|
L
 -7.2%
H
5.6
6.1
|
L
 -16.0%
H
5.6
6.9
|
L
 -1.9%
H
5.5
8.4
|
L
 4.8%
H
3.2
8.4
|
L
 40.2%
H
3.2
10.1
|
L
 -19.5%
H
0.5
10.1
|
L
 -17.4%
H
0.5
16.3
|
| Arcutis Biotherapeutics Inc |
|
2,772.1
|
22.4
|
L
 -1.6%
H
22.2
22.8
|
L
 -9.1%
H
22.2
24.5
|
L
 -16.0%
H
22.2
28.8
|
L
 -21.1%
H
22.2
30.8
|
L
 36.1%
H
11.9
31.8
|
L
 101.5%
H
1.8
31.8
|
L
 -30.9%
H
1.8
36.5
|
L
H
1.8
40.9
|
| Artelo Biosciences Inc |
|
4.8
|
6.8
|
L
 40.2%
H
6.1
8.3
|
L
 67.9%
H
3.8
8.3
|
L
 100.6%
H
3.2
8.3
|
L
 24.5%
H
3.2
8.3
|
L
 -60.3%
H
3.2
85.8
|
L
 -82.3%
H
3.2
85.8
|
L
 -98.8%
H
3.2
588.6
|
L
H
3.2
46656
|
| Assembly Biosciences Inc |
|
438.6
|
27.7
|
L
 -2.8%
H
27.5
28.3
|
L
 -6.3%
H
27.5
29.5
|
L
 -0.3%
H
25.7
30.6
|
L
 -14.9%
H
24.7
39.0
|
L
 161.9%
H
7.8
39.7
|
L
 87.9%
H
7.7
39.7
|
L
 -54.2%
H
7.7
61.4
|
L
 -57.0%
H
7.7
808.3
|
| ASP Isotopes Inc |
|
594.3
|
4.8
|
L
 -4.4%
H
4.7
5.1
|
L
 -21.4%
H
4.7
6.3
|
L
 -11.7%
H
4.7
6.5
|
L
 -17.5%
H
4.7
8.6
|
L
 11.2%
H
3.9
14.5
|
L
 259.8%
H
0.3
14.5
|
L
H
0.3
14.5
|
L
H
0.3
14.5
|
| Assertio Holdings Inc |
|
86.6
|
13.5
|
L
 8%
H
12.4
13.7
|
L
 16.1%
H
11.2
13.7
|
L
 12.0%
H
11.1
13.7
|
L
 22.1%
H
8.6
13.7
|
L
 23.4%
H
7.7
15.2
|
L
 -84.6%
H
7.7
120.2
|
L
 -76.7%
H
7.7
120.2
|
L
 -98.3%
H
7.7
1621.2
|
| ATAI Life Sciences N.V. |
|
1,314.8
|
3.6
|
L
 -0.8%
H
3.6
3.7
|
L
 -12.6%
H
3.6
4.2
|
L
 -4.7%
H
3.4
4.4
|
L
 -10.8%
H
3.3
4.7
|
L
 148.0%
H
1.2
6.8
|
L
 196.7%
H
1.0
6.8
|
L
H
1.0
22.9
|
L
H
1.0
22.9
|
| ETHZilla Corp |
|
53.0
|
2.8
|
L
 -6.4%
H
2.8
2.9
|
L
 -7.3%
H
2.8
3.3
|
L
 -20.5%
H
2.8
3.9
|
L
 -57.3%
H
2.8
7.0
|
L
 -73.9%
H
2.8
174.6
|
L
 -99.3%
H
2.8
513
|
L
 -100.0%
H
2.8
49571
|
L
H
2.8
49571
|
| Atossa Therapeutics Inc |
|
46.0
|
5.3
|
L
 -2.7%
H
5.2
5.5
|
L
 11.7%
H
4.6
5.6
|
L
 28.7%
H
3.8
5.6
|
L
 -50.1%
H
3.8
11.2
|
L
 -51.2%
H
3.8
19.4
|
L
 -48.4%
H
3.8
34.7
|
L
 -87.7%
H
3.8
147
|
L
 -99.4%
H
3.8
1133.7
|
| Atara Biotherapeutics Inc |
|
35.0
|
4.9
|
L
 -7.1%
H
4.8
5.2
|
L
 -22.7%
H
4.8
7.1
|
L
 8.2%
H
3.9
7.3
|
L
 -71.7%
H
3.9
19.1
|
L
 -32.2%
H
3.9
19.1
|
L
 -93.6%
H
0.4
79.3
|
L
 -98.8%
H
0.4
501
|
L
 -98.8%
H
0.4
1361.3
|
| Atea Pharma Inc |
|
465.3
|
5.8
|
L
 -4.7%
H
5.8
6.1
|
L
 -3.5%
H
5.8
6.3
|
L
 27.0%
H
4.5
6.5
|
L
 83.7%
H
3.1
6.5
|
L
 86.6%
H
2.5
6.5
|
L
 54.9%
H
2.5
6.5
|
L
 -92.5%
H
2.5
79.5
|
L
H
2.5
94.2
|
| Avalo Therapeutics Inc |
|
273.8
|
14.8
|
L
 -3.8%
H
14.6
15.3
|
L
 -12.6%
H
14.6
17.5
|
L
 -1.9%
H
13.6
19.1
|
L
 -23.2%
H
13.0
20.1
|
L
 92.3%
H
3.4
20.7
|
L
 572.3%
H
0.0
34.5
|
L
 -63.6%
H
0.0
44.4
|
L
 -74.9%
H
0.0
91.8
|
| Aytu BioPharma Inc |
|
27.8
|
2.6
|
L
H
2.6
2.7
|
L
 -0.4%
H
2.5
2.7
|
L
 19.4%
H
2.2
2.7
|
L
 0.8%
H
2.1
3.1
|
L
 110.6%
H
1.0
3.1
|
L
 23.3%
H
1.0
3.5
|
L
 -98.7%
H
1.0
235.3
|
L
 -100.0%
H
1.0
672000
|
| Adagene Inc (ADR) |
|
186.6
|
4.0
|
L
 1.3%
H
3.9
4.2
|
L
 35.2%
H
2.9
4.6
|
L
 20.4%
H
2.8
4.6
|
L
 112.9%
H
1.5
4.6
|
L
 118.8%
H
1.3
4.6
|
L
 149.1%
H
1.1
4.6
|
L
 -82%
H
0.9
22.1
|
L
H
0.9
31.8
|
| Addex Therapeutics Ltd (ADR) |
|
6.9
|
5.6
|
L
 -18.0%
H
5.6
6.2
|
L
 -21.7%
H
5.6
7.3
|
L
 -23.0%
H
5.6
8.0
|
L
 -32.1%
H
5.6
10.4
|
L
 -26.8%
H
5.6
12.1
|
L
 -74.4%
H
5
27.9
|
L
 -97.3%
H
5
229.6
|
L
H
5
750.4
|
| Amarin Corp (ADR) |
|
312.3
|
15.0
|
L
 -3.3%
H
14.9
15.4
|
L
 -6.0%
H
14.9
17
|
L
 -4.0%
H
13.5
17
|
L
 9.3%
H
13.1
17.3
|
L
 3473.8%
H
0.4
20.9
|
L
 874.7%
H
0.4
20.9
|
L
 125.4%
H
0.4
20.9
|
L
 979.9%
H
0.4
26.1
|
| Ascendis Pharma A/S (ADR) |
|
13,905.6
|
226.5
|
L
 -0.7%
H
224.6
228
|
L
 -5.8%
H
223.0
242.7
|
L
 1.4%
H
219.6
248.6
|
L
 11.7%
H
188.1
248.6
|
L
 34.2%
H
124.1
248.6
|
L
 109.5%
H
64.3
248.6
|
L
 57.3%
H
61.6
248.6
|
L
 1175.3%
H
11.9
248.6
|
| Alterity Therapeutics Ltd (ADR) |
|
62.5
|
3.5
|
L
 3.3%
H
3.4
3.5
|
L
 -4.7%
H
3.3
3.7
|
L
 -0.6%
H
3.3
3.8
|
L
 18.2%
H
2.7
3.8
|
L
 -14.4%
H
2.5
7
|
L
 26.4%
H
1
7
|
L
 -78.6%
H
1
27.5
|
L
 -88.7%
H
1
66.9
|
| Astrazeneca plc |
|
586,875.3
|
189.3
|
L
 -1.1%
H
187.6
190.7
|
L
 -2.9%
H
187.6
194.8
|
L
 -9.6%
H
187.6
212.7
|
L
 0.5%
H
183.6
212.7
|
L
 0.5%
H
183.6
212.7
|
L
 0.5%
H
183.6
212.7
|
L
 0.5%
H
183.6
212.7
|
L
 0.5%
H
183.6
212.7
|
| Biofrontera Inc |
|
9.9
|
0.9
|
L
 -4.5%
H
0.9
0.9
|
L
 2.4%
H
0.8
0.9
|
L
 2.4%
H
0.8
1.0
|
L
 18.1%
H
0.6
1.0
|
L
 -15.8%
H
0.5
1.2
|
L
 -93.5%
H
0.5
13.5
|
L
H
0.5
292.6
|
L
H
0.5
292.6
|
| Biomea Fusion Inc |
|
82.7
|
1.2
|
L
 -4.1%
H
1.1
1.2
|
L
 -20.4%
H
1.1
1.5
|
L
 -12.0%
H
1.1
1.6
|
L
 -13.3%
H
1.0
1.7
|
L
 -53.6%
H
0.9
3.1
|
L
 -92.4%
H
0.9
43.7
|
L
H
0.9
43.7
|
L
H
0.9
43.7
|
| Bolt Biotherapeutics Inc |
|
8.5
|
4.4
|
L
H
4.2
4.4
|
L
 4.2%
H
3.9
4.7
|
L
 -11.2%
H
3.9
5.3
|
L
 -18.5%
H
3.9
7.2
|
L
 -45.9%
H
3.9
9.7
|
L
 -84.9%
H
3.9
40.6
|
L
 -99.4%
H
3.9
799.2
|
L
H
3.9
861.4
|
| Blue Water Biotech Inc |
|
9.3
|
0.5
|
L
H
0.5
0.5
|
L
 -10.3%
H
0.5
0.6
|
L
 -33.3%
H
0.4
1.0
|
L
 -72.8%
H
0.4
2.3
|
L
 550%
H
0.1
5.9
|
L
 -50.5%
H
0.1
5.9
|
L
H
0.1
90.9
|
L
H
0.1
90.9
|
| BeyondSpring Inc |
|
74.4
|
1.8
|
L
 1.1%
H
1.8
1.8
|
L
 23.1%
H
1.4
1.9
|
L
 39.2%
H
1.2
1.9
|
L
 -4.7%
H
1.2
2.4
|
L
 3.4%
H
1.0
3.4
|
L
 46.0%
H
0.7
4
|
L
 -85.6%
H
0.5
33
|
L
H
0.5
48.5
|
| Biodexa Pharma PLC (ADR) |
|
0.6
|
0.7
|
L
 -6.3%
H
0.7
0.8
|
L
 -22.1%
H
0.7
0.9
|
L
 -42.6%
H
0.7
1.4
|
L
 -86.5%
H
0.7
4.7
|
L
 -96.5%
H
0.7
26.5
|
L
 -100.0%
H
0.7
815034.7
|
L
 -100.0%
H
0.7
36100000
|
L
 -100.0%
H
0.7
2720000000
|
| BeiGene Ltd (ADR) |
|
30,608.2
|
287.3
|
L
 -0.8%
H
285.4
292.9
|
L
 -5.9%
H
283.0
302.1
|
L
 -19.0%
H
283.0
372.7
|
L
 -6.1%
H
283.0
372.7
|
L
 25.8%
H
228.9
385.2
|
L
 28.7%
H
127.0
385.2
|
L
 -12.9%
H
118.2
426.6
|
L
 1003.8%
H
24.5
426.6
|
| Bioline Rx Ltd (ADR) |
|
11.9
|
2.7
|
L
 1.1%
H
2.6
2.8
|
L
 2.6%
H
2.6
2.8
|
L
 -2.5%
H
2.6
3.1
|
L
 -8.1%
H
2.6
3.2
|
L
 -14.9%
H
2.3
7.8
|
L
 -88.8%
H
0.1
101.2
|
L
 -97.8%
H
0.1
253.6
|
L
 -99.6%
H
0.1
1103.9
|
| Belite Bio Inc (ADR) |
|
5,758.7
|
159
|
L
 -1.5%
H
158.0
162.5
|
L
 -8.6%
H
155.5
177.9
|
L
 -9.6%
H
155.5
192.3
|
L
 3.1%
H
146.1
200
|
L
 134.5%
H
49
200
|
L
 458.5%
H
11
200
|
L
H
6
200
|
L
H
6
200
|
| Neuphoria Therapeutics Inc |
|
24.5
|
4.5
|
L
 -1.5%
H
4.5
4.6
|
L
 -2.4%
H
4.5
4.9
|
L
 11.8%
H
4.1
4.9
|
L
 19.5%
H
3.6
4.9
|
L
 -9.2%
H
3.6
21.4
|
L
 72.0%
H
0.2
21.4
|
L
H
0.2
22
|
L
H
0.2
22
|
| Capricor Therapeutics Inc |
|
1,500.2
|
30.7
|
L
 -1.5%
H
30.4
31.3
|
L
 -8.1%
H
29.4
35.1
|
L
 33.4%
H
22.8
36.5
|
L
 17.4%
H
21.1
36.5
|
L
 138.4%
H
4.3
40.4
|
L
 607.6%
H
2.7
40.4
|
L
 480.5%
H
2.6
40.4
|
L
 14.2%
H
0.9
54
|
| Cullinan Oncology Inc |
|
779.7
|
13.2
|
L
 -2.0%
H
13.1
13.5
|
L
 -11.7%
H
13.1
14.8
|
L
 8.0%
H
12.1
16.7
|
L
 37.3%
H
9.4
16.7
|
L
 45.9%
H
5.7
16.7
|
L
 15.5%
H
5.7
30.2
|
L
 -69.7%
H
5.7
43.6
|
L
H
5.7
59.9
|
| Coherus Biosciences Inc |
|
242.8
|
1.6
|
L
 -3.6%
H
1.6
1.7
|
L
 -16.9%
H
1.6
2
|
L
 0.6%
H
1.6
2.1
|
L
 20%
H
1.3
2.6
|
L
 76.1%
H
0.7
2.6
|
L
 -73.4%
H
0.7
8.7
|
L
 -89.9%
H
0.7
19.3
|
L
 -91.2%
H
0.7
32.0
|
| Cingulate Inc |
|
94.1
|
8.6
|
L
 -26.2%
H
8.5
11.1
|
L
 9.3%
H
7.8
11.9
|
L
 47.8%
H
5.8
11.9
|
L
 125.1%
H
3.8
11.9
|
L
 132.4%
H
3.2
11.9
|
L
 834.8%
H
0.2
20.8
|
L
H
0.2
20.8
|
L
H
0.2
20.8
|
| Clene Inc |
|
73.1
|
6.2
|
L
 1.3%
H
6.1
6.4
|
L
 14.2%
H
5.4
6.5
|
L
 47.2%
H
4.1
6.5
|
L
 -4.8%
H
3.9
7.0
|
L
 36.2%
H
2.3
13.5
|
L
 -75.6%
H
2.3
25.4
|
L
 -97.7%
H
2.3
356.4
|
L
H
0.5
356.4
|
| Cellectar Biosciences Inc |
|
13.9
|
3.3
|
L
 -0.9%
H
3.2
3.4
|
L
 7.2%
H
2.9
3.5
|
L
 4.8%
H
2.6
3.7
|
L
 19.3%
H
2.5
4.1
|
L
 -67.7%
H
2.5
20.6
|
L
 -92.8%
H
2.5
133.5
|
L
 -99.5%
H
2.5
627
|
L
 -100.0%
H
2.5
15300
|
| Clearmind Medicine Inc |
|
1.2
|
0.7
|
L
 -8%
H
0.6
0.9
|
L
 -31%
H
0.6
1.1
|
L
 -43.0%
H
0.6
1.3
|
L
 -75.4%
H
0.6
2.9
|
L
 -98.5%
H
0.6
52.4
|
L
 -100.0%
H
0.6
4320
|
L
 -100.0%
H
0.6
788400
|
L
H
0.6
788400
|
| Compass Therapeutics Inc |
|
972.0
|
5.3
|
L
 -3.7%
H
5.2
5.4
|
L
 -5.8%
H
5.1
5.7
|
L
 -17.8%
H
5.1
6.6
|
L
 5.9%
H
4.8
6.9
|
L
 123.4%
H
1.3
6.9
|
L
 54.4%
H
0.8
6.9
|
L
H
0.8
11
|
L
H
0.8
11
|
| Cns Pharma Inc |
|
1.3
|
2.1
|
L
 -7.1%
H
2.1
2.3
|
L
 -37.3%
H
2.1
3.6
|
L
 -35.6%
H
2.1
3.6
|
L
 -69.7%
H
2.1
8.9
|
L
 -94.3%
H
2.1
55.2
|
L
 -100.0%
H
2.1
6600000
|
L
 -100.0%
H
2.1
145800000
|
L
H
2.1
256050000
|
| Context Therapeutics Inc |
|
266.4
|
2.9
|
L
 1.4%
H
2.8
3.0
|
L
 -0.7%
H
2.7
3.6
|
L
 24.5%
H
2.1
3.6
|
L
 158.9%
H
1.1
3.6
|
L
 245.2%
H
0.5
3.6
|
L
 367.7%
H
0.5
3.6
|
L
H
0.5
10.9
|
L
H
0.5
10.9
|
| Cocrystal Pharma Inc |
|
15.6
|
1.1
|
L
 1.8%
H
1.1
1.1
|
L
 6.6%
H
1
1.1
|
L
 21.5%
H
0.9
1.1
|
L
 16.5%
H
0.9
1.2
|
L
 -31.9%
H
0.9
2.7
|
L
 -38.9%
H
0.9
3.3
|
L
 -94.3%
H
0.9
41.5
|
L
 -99.5%
H
0.9
309.6
|
| Collegium pharma Inc |
|
1,106.3
|
34.8
|
L
 -2.5%
H
34.7
35.5
|
L
 -4.8%
H
34.3
37.1
|
L
 -24.4%
H
34.3
46.4
|
L
 -28.8%
H
34.3
50.8
|
L
 17.4%
H
23.2
50.8
|
L
 46.0%
H
20.8
50.8
|
L
 37.3%
H
14.0
50.8
|
L
 126.4%
H
7.4
50.8
|
| Corcept Therapeutics Inc |
|
3,535.9
|
33.2
|
L
 -0.8%
H
32.7
33.5
|
L
 -0.9%
H
31.8
34.3
|
L
 -16.1%
H
28.7
40.5
|
L
 -59.6%
H
28.7
85.3
|
L
 -42.6%
H
28.7
117.3
|
L
 61.0%
H
20.6
117.3
|
L
 29.3%
H
15.8
117.3
|
L
 714.7%
H
4.0
117.3
|
| Cosmos Health Inc |
|
12.7
|
0.3
|
L
 -2.9%
H
0.3
0.4
|
L
 -5.6%
H
0.3
0.4
|
L
 -5.6%
H
0.3
0.4
|
L
 -32%
H
0.3
0.6
|
L
 -32%
H
0.3
1.3
|
L
 -90.2%
H
0.3
4.1
|
L
 -99.8%
H
0.3
194.3
|
L
 -99.7%
H
0.3
312.5
|
| Cumberland Pharma Inc |
|
43.7
|
2.9
|
L
 -3.0%
H
2.9
3.2
|
L
 -7.6%
H
2.9
3.4
|
L
 -24.2%
H
2.9
5.0
|
L
 -24.9%
H
2.9
5.4
|
L
 -43.5%
H
1.9
6.3
|
L
 52.1%
H
1.0
7.3
|
L
 -9.3%
H
1.0
7.5
|
L
 -33.6%
H
1.0
8.0
|
| Catalyst Pharma Inc |
|
2,775.9
|
22.7
|
L
 -2.6%
H
22.5
23.3
|
L
 -8.2%
H
22.5
24.8
|
L
 -7.8%
H
22.3
25.4
|
L
 -5.3%
H
22.1
25.5
|
L
 4.2%
H
19.1
26.6
|
L
 42.8%
H
11.1
26.6
|
L
 437.4%
H
4.2
26.6
|
L
 2004.6%
H
0.5
26.6
|
| Corbus Pharma Holdings Inc |
|
162.7
|
9.3
|
L
 -3.7%
H
9.2
9.7
|
L
 -7.7%
H
9.2
10.5
|
L
 23.3%
H
7.2
10.5
|
L
 13.7%
H
7.2
10.5
|
L
 33.2%
H
4.6
20.6
|
L
 49.5%
H
3.0
61.9
|
L
 -86.1%
H
2.1
71.7
|
L
 -82.3%
H
2.1
323.4
|
| Crinetics Pharma Inc |
|
3,884.6
|
37.1
|
L
 -2.1%
H
36.6
37.9
|
L
 -0.7%
H
35.4
38.5
|
L
 -15.1%
H
35.4
45.2
|
L
 -22.2%
H
35.4
58.0
|
L
 5.4%
H
24.1
58.0
|
L
 115.1%
H
15.2
62.5
|
L
 124.8%
H
14.8
62.5
|
L
H
10.6
62.5
|
| Corvus Pharma Inc |
|
1,186.1
|
14.2
|
L
 -8.4%
H
14.1
15.4
|
L
 -15.6%
H
14.1
17.1
|
L
 -19.0%
H
14.1
18.7
|
L
 80.6%
H
6.4
27.0
|
L
 200%
H
2.5
27.0
|
L
 1813.5%
H
0.6
27.0
|
L
 329.1%
H
0.6
27.0
|
L
H
0.6
27.0
|
| CytomX Therapeutics Inc |
|
791.3
|
4.7
|
L
 -14.3%
H
4.6
5.3
|
L
 -4.3%
H
4.6
8.2
|
L
 -11.4%
H
4.6
8.2
|
L
 13.6%
H
3.9
8.2
|
L
 641.3%
H
0.4
8.2
|
L
 151.1%
H
0.4
8.2
|
L
 -44.8%
H
0.4
10.1
|
L
 -60.9%
H
0.4
35
|
| Cyclacel Pharma Inc |
|
4.5
|
0.9
|
L
 -1.1%
H
0.9
0.9
|
L
 -4.2%
H
0.7
1.0
|
L
 -11.7%
H
0.7
1.1
|
L
 -33.1%
H
0.7
1.7
|
L
 -98.8%
H
0.7
100.8
|
L
 -100.0%
H
0.7
3168
|
L
 -100.0%
H
0.7
31068
|
L
 -100.0%
H
0.7
784800
|
| Cyclerion Therapeutics Inc |
|
5.6
|
1.5
|
L
H
1.4
1.5
|
L
 0.7%
H
1.3
1.6
|
L
 19.4%
H
1.2
1.6
|
L
 -2.6%
H
1.0
2.3
|
L
 -42.0%
H
1.0
3.8
|
L
 -86.5%
H
1.0
12.0
|
L
 -98.3%
H
1.0
97.2
|
L
H
1.0
457
|
| Cytokinetics Inc |
|
7,581.9
|
61.6
|
L
 -0.9%
H
60.8
62.0
|
L
 -4.1%
H
58.4
63.8
|
L
 -7.6%
H
58.4
70.4
|
L
 2.9%
H
58.4
71.0
|
L
 37.1%
H
29.3
71.0
|
L
 74.2%
H
26.0
110
|
L
 139.7%
H
17.7
110
|
L
 894.5%
H
5.8
110
|
| Cellectis (ADR) |
|
349.1
|
3.5
|
L
 0.6%
H
3.4
3.7
|
L
 -9.2%
H
3.3
3.8
|
L
 -10.6%
H
3.3
4.3
|
L
 -12.6%
H
3.3
5.1
|
L
 184.4%
H
1.1
5.5
|
L
 84.6%
H
1.0
5.5
|
L
 -83.7%
H
1.0
22.2
|
L
 -86.4%
H
1.0
38.9
|
| Centessa Pharma PLC (ADR) |
|
4,204.0
|
28.4
|
L
 -1.8%
H
28.2
29.2
|
L
 3.1%
H
25.7
29.2
|
L
 14.0%
H
24.0
29.2
|
L
 13.9%
H
21.5
29.2
|
L
 65.4%
H
9.6
30.6
|
L
 629.2%
H
3.4
30.6
|
L
H
2.9
30.6
|
L
H
2.9
30.6
|
| Connect Biopharma Holdings Ltd (ADR) |
|
146.5
|
2.6
|
L
 -3.0%
H
2.6
2.7
|
L
 -5.7%
H
2.6
3.0
|
L
 -7.4%
H
2.4
3.2
|
L
 16.9%
H
2.0
3.2
|
L
 220.7%
H
0.5
3.3
|
L
 139.1%
H
0.5
3.3
|
L
H
0.5
29.3
|
L
H
0.5
29.3
|
| Dare Bioscience Inc |
|
20.3
|
1.4
|
L
 -2.1%
H
1.4
1.5
|
L
 -4.7%
H
1.4
1.5
|
L
 -15.0%
H
1.4
1.7
|
L
 -40.3%
H
1.4
2.4
|
L
 -50.7%
H
1.4
9.2
|
L
 -87.9%
H
0.3
13.2
|
L
 -94.6%
H
0.3
30.1
|
L
 -99.4%
H
0.3
519.6
|
| Day One Biopharma Inc |
|
2,200.2
|
21.3
|
L
 0.1%
H
21.3
21.3
|
L
 0.1%
H
21.2
21.4
|
L
 79.3%
H
10.0
21.4
|
L
 143.2%
H
8.4
21.4
|
L
 145.7%
H
5.6
21.4
|
L
 17.9%
H
5.6
21.4
|
L
H
5.4
28.7
|
L
H
5.4
28.7
|
| Journey Medical Corp |
|
244.1
|
7.3
|
L
 -2.1%
H
7.3
7.7
|
L
 -9.9%
H
7.2
8.3
|
L
 -9.4%
H
7.2
9.1
|
L
 -5.4%
H
7.0
9.6
|
L
 38.2%
H
5.2
9.6
|
L
 389.3%
H
1.0
9.6
|
L
H
1.0
10.2
|
L
H
1.0
10.2
|
| Diffusion Pharma Inc |
|
-
|
4.5
|
L
 5.1%
H
4.2
4.6
|
L
 -6.8%
H
4.0
5.0
|
L
 -0.2%
H
3.6
5.2
|
L
 -43.3%
H
3.6
8.6
|
L
 -48.4%
H
3.6
13.1
|
L
 -50.2%
H
3.6
14.4
|
L
 -94.4%
H
3.6
84
|
L
 -100.0%
H
3.6
17437.5
|
| DiaMedica Therapeutics Inc |
|
376.5
|
7.2
|
L
 1.0%
H
6.9
7.3
|
L
 -9.1%
H
6.9
7.9
|
L
 -16.9%
H
6.9
8.8
|
L
 -11.9%
H
6.9
9.0
|
L
 20.7%
H
3.2
10.4
|
L
 301.7%
H
1.5
10.4
|
L
 -28.3%
H
1.1
10.7
|
L
 171.8%
H
1.1
13.8
|
| Dermata Therapeutics Inc |
|
3.4
|
1.2
|
L
 -2.5%
H
1.2
1.3
|
L
 -6.3%
H
1.2
1.4
|
L
 -5.6%
H
1.1
2.3
|
L
 -48.3%
H
1.1
4.7
|
L
 1.7%
H
0.6
7.1
|
L
 -33.1%
H
0.2
7.1
|
L
H
0.2
111.2
|
L
H
0.2
111.2
|
| DBV Tech (ADR) |
|
1,080.9
|
19.4
|
L
 -2.1%
H
19.2
19.9
|
L
 -17.5%
H
18.6
22.9
|
L
 -6.2%
H
18.6
24.1
|
L
 -13.9%
H
16.5
25.4
|
L
 315.0%
H
3.9
26.2
|
L
 29.5%
H
0.5
26.2
|
L
 -65.1%
H
0.5
68.8
|
L
 -93.6%
H
0.5
505.7
|
| Edesa Biotech Inc |
|
58.4
|
7.0
|
L
 -0.1%
H
6.7
7.6
|
L
 1.3%
H
4.9
8.1
|
L
 585.3%
H
0.7
8.7
|
L
 359.9%
H
0.7
8.7
|
L
 186.5%
H
0.7
8.7
|
L
 0.9%
H
0.7
8.7
|
L
 -83.5%
H
0.7
84
|
L
 -99.6%
H
0.7
1734.6
|
| Eledon Pharma Inc |
|
241.3
|
3.0
|
L
 5.2%
H
2.9
3.1
|
L
 4.5%
H
2.7
3.1
|
L
 43.6%
H
2.1
3.2
|
L
 93.0%
H
1.4
3.2
|
L
 -16.5%
H
1.4
4.6
|
L
 35.9%
H
1.1
5.4
|
L
 -78.3%
H
1.1
16.6
|
L
 -99.7%
H
1.1
1425.6
|
| Enanta Pharma Inc |
|
368.5
|
12.7
|
L
 -4.3%
H
12.6
13.7
|
L
 -9.0%
H
12.5
14.3
|
L
 -8.4%
H
12.5
15.7
|
L
 -10.9%
H
12.1
17.2
|
L
 108.2%
H
4.1
17.2
|
L
 -69.8%
H
4.1
43.1
|
L
 -75.8%
H
4.1
102
|
L
 -53.3%
H
4.1
127.8
|
| Entera Bio Ltd |
|
64.7
|
1.4
|
L
 2.2%
H
1.4
1.4
|
L
 -5.4%
H
1.3
1.6
|
L
 -0.7%
H
1.2
1.7
|
L
 -28.4%
H
1
2.1
|
L
 -27.7%
H
1
3.2
|
L
 30.6%
H
0.5
3.4
|
L
 -75.9%
H
0.5
8.7
|
L
H
0.5
10.2
|
| Evolus Inc |
|
312.3
|
4.8
|
L
 -2.2%
H
4.8
4.9
|
L
 -9.1%
H
4.7
5.4
|
L
 9.3%
H
4.1
6.3
|
L
 -32.2%
H
4.1
7.3
|
L
 -64.7%
H
4.1
13.7
|
L
 -42.7%
H
4.1
17.8
|
L
 -63.9%
H
4.1
17.8
|
L
H
2.9
39.5
|
| Erasca Inc |
|
4,194.9
|
13.6
|
L
 1.4%
H
13.2
13.8
|
L
 -13.0%
H
12.9
15.8
|
L
 8.8%
H
12.2
16.4
|
L
 272.3%
H
3.3
16.4
|
L
 828.1%
H
1.0
16.4
|
L
 342.8%
H
1.0
16.4
|
L
H
1.0
24.5
|
L
H
1.0
24.5
|
| Esperion Therapeutics Inc |
|
597.7
|
2.5
|
L
 -7.8%
H
2.5
2.7
|
L
 -7.4%
H
2.4
2.8
|
L
 -29.6%
H
2.4
3.7
|
L
 -31.5%
H
2.4
4.2
|
L
 62.3%
H
0.7
4.2
|
L
 61.3%
H
0.7
4.2
|
L
 -91.7%
H
0.7
30.5
|
L
 -82.6%
H
0.7
82.7
|
| Eton Pharma Inc |
|
510.9
|
19.1
|
L
 0.7%
H
18.8
19.6
|
L
 9.5%
H
17
19.9
|
L
 11.1%
H
16.1
20.0
|
L
 20.4%
H
14.3
20.0
|
L
 24.6%
H
11.1
23
|
L
 388.5%
H
2.4
23
|
L
 137.5%
H
2.0
23
|
L
H
2.0
23
|
| Exelixis Inc |
|
10,697.4
|
41.2
|
L
 -1.5%
H
41.0
41.9
|
L
 -0.2%
H
40.5
42.1
|
L
 -6.6%
H
39.7
45.9
|
L
 -1.9%
H
39.7
47.2
|
L
 11.3%
H
32.4
49.6
|
L
 134.7%
H
17.9
49.6
|
L
 77.9%
H
14.9
49.6
|
L
 995.5%
H
3.6
49.6
|
| Hyperion DeFi Inc |
|
31.4
|
3.7
|
L
 -1.3%
H
3.6
4
|
L
 12.8%
H
3.2
4
|
L
 -2.1%
H
2.8
4
|
L
 26.2%
H
2.8
4.5
|
L
 117.0%
H
0.9
17.2
|
L
 -98.4%
H
0.0
468
|
L
 -99.3%
H
0.0
530.4
|
L
H
0.0
859.2
|
| EyePoint Pharma Inc |
|
1,139.7
|
13.7
|
L
 -1.7%
H
13.4
14.0
|
L
 -11.5%
H
12.9
15.6
|
L
 -8.4%
H
12.9
18.9
|
L
 -18.0%
H
12.1
19
|
L
 106.0%
H
3.9
19.1
|
L
 481.3%
H
2.2
31.0
|
L
 14.5%
H
2.2
31.0
|
L
 -45.4%
H
2.2
42.5
|
| Evotec SE (ADR) |
|
867.4
|
2.4
|
L
 -1.2%
H
2.4
2.5
|
L
 -8.6%
H
2.3
2.6
|
L
 -30.9%
H
2.3
3.7
|
L
 -17.0%
H
2.3
3.9
|
L
 -32.0%
H
2.3
4.8
|
L
 -74.7%
H
2.3
13.5
|
L
 -86.3%
H
2.3
26.6
|
L
 37.9%
H
1.8
26.6
|
| Fortress Biotech Inc |
|
100.3
|
3.2
|
L
 3.5%
H
3.1
3.3
|
L
 -3.9%
H
3.0
3.4
|
L
 -7.7%
H
3.0
4.2
|
L
 -5.8%
H
2.9
4.5
|
L
 84.6%
H
1.3
4.5
|
L
 -69.2%
H
1.2
12.8
|
L
 -94.8%
H
1.2
91.5
|
L
 -93.0%
H
1.2
91.5
|
| Fennec Pharma Inc |
|
252.7
|
7.4
|
L
 -4.6%
H
7.4
7.8
|
L
 -6.2%
H
7.4
8.1
|
L
 -14.8%
H
7.3
9.2
|
L
 -1.9%
H
7.3
9.2
|
L
 17.1%
H
4.7
9.9
|
L
 -10.3%
H
4.0
11.9
|
L
 -1.1%
H
3.8
11.9
|
L
 302.2%
H
1.6
15.0
|
| Kyntra Bio Inc |
|
28.7
|
7.1
|
L
 -3.7%
H
7.0
7.4
|
L
 -0.4%
H
6.7
7.5
|
L
 -3.1%
H
6.7
9.0
|
L
 -18.0%
H
6.7
9.8
|
L
 -36.2%
H
4.9
12.6
|
L
 -98.6%
H
4.5
522.5
|
L
 -99.2%
H
4.5
903.1
|
L
 -98.3%
H
4.5
1713.8
|
| Q32 Bio Inc |
|
74.6
|
5.8
|
L
 -5.4%
H
5.6
6.3
|
L
 -3.2%
H
5.6
7.8
|
L
 35.5%
H
4.0
7.8
|
L
 101.4%
H
2.8
7.8
|
L
 164.8%
H
1.3
7.8
|
L
 -66.1%
H
1.3
53.8
|
L
 -96.9%
H
1.3
200.5
|
L
H
1.3
572.4
|
| Amicus Therapeutics Inc |
|
4,515.3
|
14.4
|
L
 0.1%
H
14.4
14.4
|
L
 0.1%
H
14.4
14.4
|
L
 0.6%
H
14.3
14.4
|
L
 30.7%
H
10.6
14.4
|
L
 57.7%
H
5.5
14.4
|
L
 27.9%
H
5.5
14.6
|
L
 36.4%
H
5.5
14.6
|
L
 97.8%
H
4.4
25.4
|
| Fulcrum Therapeutics Inc |
|
462.2
|
6.9
|
L
 -6.6%
H
6.8
7.5
|
L
 -13.4%
H
6.8
8.1
|
L
 -34.9%
H
6.8
12.0
|
L
 -42.6%
H
6.8
12.9
|
L
 122.4%
H
2.3
15.7
|
L
 101.2%
H
2.3
15.7
|
L
 -44.7%
H
2.3
33.1
|
L
H
2.3
33.1
|
| GH Research PLC |
|
936.6
|
15.1
|
L
 -1.7%
H
14.9
15.4
|
L
 -4.2%
H
14.6
16.0
|
L
 -5.6%
H
14.4
16.5
|
L
 19.0%
H
12.2
19
|
L
 41.8%
H
8.0
19.5
|
L
 95.6%
H
5.1
20.5
|
L
H
5.1
30.4
|
L
H
5.1
30.4
|
| Galmed Pharma Ltd |
|
4.0
|
0.6
|
L
H
0.6
0.6
|
L
H
0.6
0.7
|
L
 7.0%
H
0.5
0.7
|
L
 -33.7%
H
0.5
1
|
L
 -77.0%
H
0.5
2.7
|
L
 -99.3%
H
0.2
93.6
|
L
 -99.9%
H
0.2
734.4
|
L
 -99.9%
H
0.2
4870.8
|
| Galecto Inc |
|
1,283.7
|
21.3
|
L
 -11.3%
H
20.9
23.7
|
L
 -16.5%
H
20.9
27.6
|
L
 -28.8%
H
20.9
34.0
|
L
 -19.1%
H
19.4
38.3
|
L
 422.3%
H
2.0
38.3
|
L
 1009.9%
H
0.5
38.3
|
L
 166.4%
H
0.5
38.3
|
L
H
0.5
38.3
|
| GlycoMimetics Inc |
|
716.3
|
11.1
|
L
 -4.2%
H
11
11.8
|
L
 -11.6%
H
11
13
|
L
 19.0%
H
9.2
13.5
|
L
 -11.1%
H
8.7
14.7
|
L
 -58.7%
H
8.7
28.8
|
L
 -92.1%
H
8.7
353
|
L
 -96.8%
H
8.7
416
|
L
 -98.1%
H
8.7
2605
|
| Genelux Corp |
|
116.3
|
2.6
|
L
 -0.8%
H
2.6
2.6
|
L
 -7.1%
H
2.5
2.9
|
L
 1.6%
H
2.5
3.0
|
L
 -37.4%
H
2.3
5.0
|
L
 -30.3%
H
2.0
8.5
|
L
 -90.5%
H
1.6
41.0
|
L
H
1.6
41.0
|
L
H
1.6
41.0
|
| Genprex Inc |
|
4.6
|
2.0
|
L
H
2.0
2.1
|
L
 1%
H
1.9
2.1
|
L
 12.2%
H
1.8
2.6
|
L
 -12.9%
H
1.7
3.6
|
L
 405%
H
0.1
13.0
|
L
 159.0%
H
0.1
13.0
|
L
 -61.7%
H
0.1
13.0
|
L
H
0.1
19.5
|
| Gossamer Bio Inc |
|
99.5
|
0.4
|
L
 -8.5%
H
0.4
0.5
|
L
 -15.7%
H
0.4
0.5
|
L
 -80%
H
0.3
2.2
|
L
 -88.0%
H
0.3
3.8
|
L
 -69.1%
H
0.3
3.9
|
L
 -55.2%
H
0.3
3.9
|
L
 -95.7%
H
0.3
15.2
|
L
H
0.3
27.2
|
| GT Biopharma Inc |
|
13.3
|
0.4
|
L
 -2.3%
H
0.4
0.4
|
L
H
0.4
0.5
|
L
 -8.7%
H
0.4
0.5
|
L
 -40%
H
0.4
0.9
|
L
 -82.5%
H
0.4
3.9
|
L
 -20.8%
H
0.2
10.7
|
L
 -93.6%
H
0.2
19.7
|
L
 -100.0%
H
0.2
4845
|
| Genmab (ADR) |
|
15,955.8
|
26.0
|
L
 -1.6%
H
25.9
26.4
|
L
 -7.2%
H
25.9
27.7
|
L
 -13.5%
H
25.9
29.9
|
L
 -18.2%
H
25.9
35.4
|
L
 24.8%
H
17.2
35.4
|
L
 -27.6%
H
17.2
43
|
L
 -22.8%
H
17.2
49.1
|
L
 109.3%
H
12.1
49.1
|
| Genenta Science SpA (ADR) |
|
18.5
|
0.8
|
L
 -1.3%
H
0.8
0.9
|
L
 -8.1%
H
0.8
0.9
|
L
 -12.2%
H
0.8
1.1
|
L
 -43.2%
H
0.7
1.7
|
L
 -79.7%
H
0.7
10
|
L
 -88.1%
H
0.7
10
|
L
H
0.7
13.1
|
L
H
0.7
13.1
|
| Grifols SA (ADR) - Level III |
|
5,322.1
|
7.8
|
L
 -2.5%
H
7.8
8.0
|
L
 -4.6%
H
7.8
8.2
|
L
 -18.1%
H
7.8
9.8
|
L
 -12.2%
H
7.8
9.8
|
L
 -3.5%
H
6.2
11.1
|
L
 16.5%
H
5.3
12.2
|
L
 -52.8%
H
5.3
19.1
|
L
 -48.3%
H
5.3
25.7
|
| Hoth Therapeutics Inc |
|
15.7
|
1.0
|
L
 -2.9%
H
1
1.0
|
L
 1%
H
1.0
1.3
|
L
 3.1%
H
1.0
1.3
|
L
 -5.6%
H
0.8
1.3
|
L
 -13.7%
H
0.7
2.1
|
L
 -51.2%
H
0.6
4.3
|
L
 -98.1%
H
0.6
78.8
|
L
H
0.6
347
|
| Werewolf Therapeutics Inc |
|
40.3
|
0.8
|
L
 -4.6%
H
0.8
0.9
|
L
 12.2%
H
0.7
0.9
|
L
 25.8%
H
0.5
0.9
|
L
 -22.4%
H
0.5
0.9
|
L
 -29.1%
H
0.5
2.4
|
L
 -65.8%
H
0.5
8.2
|
L
H
0.5
24.0
|
L
H
0.5
24.0
|
| Harmony Biosciences Holdings Inc |
|
1,604.5
|
27.7
|
L
 -2.2%
H
27.7
28.5
|
L
 -3.5%
H
27.2
29.0
|
L
 -24.9%
H
25.9
36.7
|
L
 -28.5%
H
25.9
39.6
|
L
 -19.2%
H
25.5
40.9
|
L
 -33.8%
H
18.6
45.2
|
L
 -9.8%
H
18.6
62.1
|
L
H
18.6
62.1
|
| Harrow Health Inc |
|
1,310.5
|
35.2
|
L
 -0.1%
H
34.6
35.6
|
L
 -2.4%
H
33.7
37.1
|
L
 -30.4%
H
33.7
54.5
|
L
 -20.7%
H
33.7
54.9
|
L
 50.9%
H
20.9
54.9
|
L
 102.8%
H
7.6
59.2
|
L
 357.1%
H
5.4
59.2
|
L
 748.2%
H
1.4
59.2
|
| HUTCHMED (China) Ltd (ADR) |
|
2,422.1
|
14.1
|
L
 -1.5%
H
14.0
14.4
|
L
 1.4%
H
13.9
15.0
|
L
 -5.3%
H
13.1
15.4
|
L
 6.3%
H
13.1
16.3
|
L
 -6.9%
H
11.5
19.5
|
L
 -2.7%
H
10.7
21.9
|
L
 -51.6%
H
7.4
43.9
|
L
 5.1%
H
7.4
43.9
|
| ImmunityBio Inc |
|
8,780.1
|
8.5
|
L
 4.0%
H
8.1
8.8
|
L
 6.6%
H
7.8
9.3
|
L
 41.9%
H
6.1
12.4
|
L
 304.7%
H
2.0
12.4
|
L
 193.5%
H
1.8
12.4
|
L
 505.7%
H
1.3
12.4
|
L
 -76.2%
H
1.2
39.6
|
L
H
1.2
40.8
|
| Ideaya Biosciences Inc |
|
2,935.6
|
33.4
|
L
 -2.5%
H
33.2
34.3
|
L
 -3.8%
H
32.2
35.3
|
L
 8.7%
H
30.5
35.7
|
L
 -0.9%
H
29.5
39.3
|
L
 74.8%
H
13.5
39.3
|
L
 123.0%
H
13.3
47.7
|
L
 42.6%
H
8.1
47.7
|
L
H
3.0
47.7
|
| Inhibikase Therapeutics Inc |
|
224.3
|
1.9
|
L
 -5.6%
H
1.8
2.0
|
L
 -5.1%
H
1.8
2.1
|
L
 9.5%
H
1.7
2.3
|
L
 16.4%
H
1.5
2.3
|
L
 -21.6%
H
1.3
2.6
|
L
 -52.6%
H
0.8
4.9
|
L
 -95.0%
H
0.8
41.8
|
L
H
0.8
70.8
|
| Immix Biopharma Inc |
|
534.3
|
10.1
|
L
 -9.3%
H
9.9
11.2
|
L
 -3.0%
H
9.8
11.6
|
L
 24.3%
H
7.4
11.6
|
L
 81.5%
H
4.2
11.6
|
L
 483.2%
H
1.3
11.6
|
L
 454.4%
H
1.3
11.6
|
L
H
0.7
11.6
|
L
H
0.7
11.6
|
| Immuneering Corp (Class A) |
|
304.8
|
4.7
|
L
 -1.7%
H
4.7
4.9
|
L
 -16.0%
H
4.7
5.8
|
L
 -7.8%
H
4.7
5.8
|
L
 -14.2%
H
4.0
8.5
|
L
 181.0%
H
1.1
10.1
|
L
 -41.5%
H
1
14.3
|
L
H
1
34.0
|
L
H
1
34.0
|
| Immunic Inc |
|
152.6
|
1.2
|
L
 -2.5%
H
1.2
1.2
|
L
 -9.3%
H
1.1
1.5
|
L
 27.2%
H
0.8
1.5
|
L
 101.7%
H
0.5
1.5
|
L
 2.6%
H
0.5
1.5
|
L
 -29.1%
H
0.5
3.1
|
L
 -92.5%
H
0.5
17.0
|
L
 -99.7%
H
0.5
390
|
| Incyte |
|
18,293.4
|
91.9
|
L
 -2.4%
H
91.6
93.9
|
L
 -4.3%
H
91.2
96.5
|
L
 -9.1%
H
91.2
103.7
|
L
 -5.9%
H
91.2
112.3
|
L
 48.2%
H
53.6
112.3
|
L
 24.9%
H
50.3
112.3
|
L
 14.6%
H
50.3
112.3
|
L
 45.8%
H
50.3
153.2
|
| Indaptus Therapeutics Inc |
|
4.1
|
1.8
|
L
 -6.1%
H
1.8
2.0
|
L
 -1.6%
H
1.7
2.0
|
L
 1.7%
H
1.7
2.2
|
L
 -14.0%
H
1.5
3.7
|
L
 127.2%
H
0.3
13.4
|
L
 13.6%
H
0.3
13.4
|
L
 -90.7%
H
0.3
28.8
|
L
 -99.4%
H
0.3
8800
|
| Indivior PLC |
|
3,872.0
|
31.0
|
L
 -1.2%
H
30.9
31.9
|
L
 -7.1%
H
29.4
35.3
|
L
 -10.9%
H
29.4
35.6
|
L
 -13.9%
H
29.4
37.7
|
L
 209.9%
H
8.6
38
|
L
 84.7%
H
7.3
38
|
L
 1669.1%
H
1.6
38
|
L
 1228.8%
H
0.4
38
|
| InMed Pharma Inc |
|
2.6
|
0.9
|
L
H
0.9
0.9
|
L
 8.5%
H
0.8
0.9
|
L
 4.7%
H
0.7
1.0
|
L
 -25.8%
H
0.7
1.4
|
L
 -67.5%
H
0.7
8.0
|
L
 -95.8%
H
0.7
41.6
|
L
 -100.0%
H
0.7
2175
|
L
 -99.9%
H
0.7
32175
|
| Inovio Pharma Inc |
|
114.5
|
1.7
|
L
 -1.2%
H
1.6
1.7
|
L
 -4.1%
H
1.6
1.8
|
L
 1.8%
H
1.6
2.0
|
L
 -36.2%
H
1.5
2.6
|
L
 -21.3%
H
1.3
3.0
|
L
 52.3%
H
0.3
14.8
|
L
 -84.2%
H
0.3
14.8
|
L
 -76.2%
H
0.3
33.8
|
| Insmed Inc |
|
30,849.8
|
143.1
|
L
 -0.6%
H
141.4
143.9
|
L
 -0.5%
H
135.7
147.4
|
L
 -4.9%
H
135.7
167.4
|
L
 -27.9%
H
135.7
186.2
|
L
 84.0%
H
60.4
212.8
|
L
 721.6%
H
16.0
212.8
|
L
 281.8%
H
16.0
212.8
|
L
 1161.0%
H
9.0
212.8
|
| Innoviva Inc |
|
1,631.1
|
22.0
|
L
 -0.2%
H
21.7
22.1
|
L
 -1.7%
H
21.7
22.4
|
L
 -7.7%
H
21.7
25.1
|
L
 9.8%
H
19
25.1
|
L
 25.6%
H
16.5
25.1
|
L
 97.0%
H
11.0
25.1
|
L
 79.5%
H
10.6
25.1
|
L
 97.3%
H
7.6
25.1
|
| Ionis Pharma Inc |
|
11,781.5
|
71.3
|
L
 -1.4%
H
70.9
72.3
|
L
 -5.7%
H
70.4
76
|
L
 -12.3%
H
70.4
85.5
|
L
 -7.5%
H
70.4
86.7
|
L
 107.9%
H
24.0
86.7
|
L
 102.7%
H
24.0
86.7
|
L
 33.7%
H
24.0
86.7
|
L
 93.1%
H
19.6
86.7
|
| Ironwood Pharma Inc (Class A) |
|
520.2
|
3.2
|
L
 -1.9%
H
3.2
3.3
|
L
 -13.8%
H
3.1
3.8
|
L
 -33.3%
H
3.0
4.8
|
L
 -5.3%
H
3.0
5.8
|
L
 107.1%
H
0.5
5.8
|
L
 -69.2%
H
0.5
15.7
|
L
 -72.3%
H
0.5
15.7
|
L
 -62.6%
H
0.5
17.7
|
| Iterum Therapeutics PLC |
|
9.1
|
0.2
|
L
H
0.2
0.2
|
L
 -5.6%
H
0.2
0.2
|
L
 -34.6%
H
0.1
0.3
|
L
 -56.4%
H
0.1
0.4
|
L
 -87.9%
H
0.1
1.5
|
L
 -84.3%
H
0.1
3.0
|
L
 -99.3%
H
0.1
37.8
|
L
H
0.1
195
|
| I-Mab (ADR) |
|
332.0
|
2.9
|
L
 -0.7%
H
2.8
3.0
|
L
 -11.1%
H
2.7
3.4
|
L
 -10.6%
H
2.7
3.9
|
L
 -30.3%
H
2.7
5.2
|
L
 238.8%
H
0.6
6.8
|
L
 -20.7%
H
0.6
6.8
|
L
 -94.9%
H
0.6
85.4
|
L
H
0.6
85.4
|
| Immuron Ltd (ADR) |
|
5.8
|
0.7
|
L
 -5.3%
H
0.7
0.7
|
L
 -18.4%
H
0.7
0.9
|
L
 1.4%
H
0.7
0.9
|
L
 -24.5%
H
0.7
1.3
|
L
 -61.0%
H
0.7
2.4
|
L
 -62.4%
H
0.7
6.0
|
L
 -89.1%
H
0.7
6.8
|
L
H
0.7
29.0
|
| Innate Pharma (ADR) |
|
123.7
|
1.3
|
L
 -1.5%
H
1.3
1.4
|
L
 -19.5%
H
1.3
1.6
|
L
 -21.9%
H
1.3
1.8
|
L
 -27.1%
H
1.3
1.9
|
L
 -34.7%
H
1.3
2.6
|
L
 -55.9%
H
1.3
3.6
|
L
 -71.3%
H
1.3
12.0
|
L
H
1.3
12.0
|
| Jaguar Health Inc |
|
5.0
|
0.5
|
L
 -6.3%
H
0.4
0.5
|
L
 -4.3%
H
0.4
0.6
|
L
 -27.4%
H
0.4
1.0
|
L
 -62.2%
H
0.4
1.9
|
L
 -96.2%
H
0.4
15.5
|
L
 -99.1%
H
0.4
76.2
|
L
 -100.0%
H
0.4
30780
|
L
 -100.0%
H
0.4
999999
|
| Jazz Pharma PLC |
|
10,997.1
|
178.6
|
L
 -1.5%
H
178.3
182.7
|
L
 -3.9%
H
177.6
186
|
L
 6.4%
H
166.6
198
|
L
 8.3%
H
157.0
198
|
L
 27.4%
H
95.5
198
|
L
 32.2%
H
95.5
198
|
L
 3.2%
H
95.5
198
|
L
 50.6%
H
86.9
198
|
| Kala Pharma Inc |
|
227.8
|
0.3
|
L
H
0.2
0.3
|
L
 -13.8%
H
0.2
0.5
|
L
 -37.5%
H
0.2
0.5
|
L
 -57.6%
H
0.2
0.7
|
L
 -96.4%
H
0.2
20.6
|
L
 -98.2%
H
0.2
20.6
|
L
 -99.9%
H
0.2
419.2
|
L
H
0.2
1337.5
|
| KalVista Pharma Inc |
|
806.2
|
16.0
|
L
 -3.7%
H
15.9
16.7
|
L
 -13.5%
H
15.9
18.4
|
L
 6.4%
H
14.8
18.7
|
L
 7.4%
H
14.2
19
|
L
 27.7%
H
9.2
19
|
L
 115.8%
H
6.3
19
|
L
 -55.5%
H
4.1
35.7
|
L
 72.6%
H
4.1
45
|
| Kiniksa Pharma Ltd (Class A) |
|
3,487.0
|
45.6
|
L
 -3.1%
H
45.3
47.0
|
L
 -3.1%
H
44.9
47.8
|
L
 0.4%
H
41.1
49.1
|
L
 9.9%
H
37.0
49.1
|
L
 98.4%
H
18.3
49.1
|
L
 299.3%
H
10.3
49.1
|
L
 102.8%
H
7.4
49.1
|
L
H
5.0
49.1
|
| Kiora Pharma Inc |
|
7.5
|
2.1
|
L
 -2.4%
H
2.1
2.1
|
L
 -6.0%
H
2.0
2.2
|
L
 1.5%
H
1.9
2.2
|
L
H
1.9
2.5
|
L
 -37.7%
H
1.8
4.2
|
L
 -39.5%
H
0.4
5.6
|
L
 -99.1%
H
0.4
257.2
|
L
 -99.9%
H
0.4
2400
|
| Karyopharm Therapeutics Inc |
|
152.3
|
8.3
|
L
 -1.0%
H
8.0
8.6
|
L
 0.9%
H
7.3
8.9
|
L
 -11.7%
H
7.3
11.0
|
L
 37.9%
H
5.9
11.0
|
L
 35.2%
H
3.5
11.0
|
L
 -83.7%
H
0.6
73.1
|
L
 -95.6%
H
0.6
221.0
|
L
 -92.9%
H
0.6
444.2
|
| Keros Therapeutics Inc |
|
214.3
|
10.9
|
L
 -4.1%
H
10.8
11.4
|
L
 -6.1%
H
10.5
11.5
|
L
 -34.2%
H
10.5
16.7
|
L
 -47.8%
H
10.5
21.8
|
L
 -6.5%
H
9.1
22.6
|
L
 -74.5%
H
9.1
73
|
L
 -81.8%
H
9.1
73
|
L
H
9.1
88.8
|
| Pasithea Therapeutics Corp |
|
19.4
|
0.8
|
L
 -2.3%
H
0.8
0.9
|
L
 2.4%
H
0.8
0.9
|
L
 21.7%
H
0.7
0.9
|
L
 -26.3%
H
0.7
1.3
|
L
 -25.7%
H
0.3
3.8
|
L
 95.3%
H
0.3
9.3
|
L
H
0.3
9.3
|
L
H
0.3
9.3
|
| Kazia Therapeutics Ltd (ADR) |
|
81.5
|
7.2
|
L
 -4.5%
H
7.0
8
|
L
 -15.6%
H
7.0
9
|
L
 34.6%
H
5.2
10.5
|
L
 -21.1%
H
4.9
11.1
|
L
 43.8%
H
2.9
17.4
|
L
 -84.9%
H
2.9
84
|
L
 -98.7%
H
2.9
744.5
|
L
 -98.3%
H
2.9
792.5
|
| Lexaria Bioscience Corp |
|
17.9
|
0.7
|
L
 -1.4%
H
0.7
0.7
|
L
 -1.4%
H
0.7
0.8
|
L
 10.8%
H
0.6
0.9
|
L
 5.9%
H
0.5
0.9
|
L
 -51.0%
H
0.5
1.9
|
L
 -71.8%
H
0.5
6.9
|
L
 -89.7%
H
0.5
12.5
|
L
 -81.5%
H
0.5
76.2
|
| Lifecore Biomedical Inc |
|
163.4
|
4.4
|
L
H
4.2
4.5
|
L
 -36.8%
H
4.1
7.0
|
L
 -39.1%
H
4.1
7.5
|
L
 -48.5%
H
4.1
9.0
|
L
 -33.4%
H
4.1
9.0
|
L
 161.1%
H
1.8
11.5
|
L
 -62.5%
H
1.5
12.9
|
L
 -57.9%
H
1.5
15.6
|
| Ligand Pharma Inc (Class B) |
|
4,162.1
|
208.7
|
L
 -1.1%
H
201.9
213.2
|
L
 -1.7%
H
196.2
227.9
|
L
 11.3%
H
178.7
227.9
|
L
 7.3%
H
175.9
227.9
|
L
 89.8%
H
93.6
227.9
|
L
 189.2%
H
49.3
227.9
|
L
 94.9%
H
46.8
227.9
|
L
 232.7%
H
36.9
227.9
|
| Atyr Pharma Inc |
|
80.3
|
0.8
|
L
 -6.8%
H
0.8
0.9
|
L
 -12.8%
H
0.8
0.9
|
L
 -16.3%
H
0.8
1.1
|
L
 15.5%
H
0.7
1.1
|
L
 -79.6%
H
0.6
7.3
|
L
 -56.4%
H
0.6
7.3
|
L
 -85.4%
H
0.6
13.1
|
L
 -98.9%
H
0.6
90.9
|
| Lipocine Inc |
|
43.2
|
7.8
|
L
 1.4%
H
7.5
8.0
|
L
 -4.1%
H
7.2
9.3
|
L
 -17.7%
H
7.2
10.5
|
L
 112.0%
H
3.6
12.4
|
L
 122.3%
H
2.5
12.4
|
L
 31.6%
H
2.3
12.4
|
L
 -76.0%
H
2.3
32.1
|
L
 -95.3%
H
2.3
215.2
|
| Liquidia Corp |
|
3,183.6
|
36.1
|
L
 -2.0%
H
35.6
37.1
|
L
 -7.0%
H
35.1
39.6
|
L
 6.8%
H
29.1
39.6
|
L
 6.2%
H
29.1
46.7
|
L
 144.3%
H
11.3
46.7
|
L
 400.4%
H
5.7
46.7
|
L
 1163.3%
H
2.3
46.7
|
L
H
2.3
46.7
|
| Lisata Therapeutics Inc |
|
45.3
|
5.0
|
L
 -0.2%
H
5.0
5.1
|
L
 -0.2%
H
5.0
5.1
|
L
 10.1%
H
4.0
5.1
|
L
 149.8%
H
1.8
5.1
|
L
 110.9%
H
1.8
5.1
|
L
 51.7%
H
1.8
5.1
|
L
 -83.9%
H
1.8
32.6
|
L
 -96.0%
H
1.8
174.8
|
| Lantern Pharma Inc |
|
25.2
|
2.3
|
L
 -3.4%
H
2.2
2.4
|
L
 -18.5%
H
2.2
2.8
|
L
 -17.9%
H
2.2
3.1
|
L
 -29.5%
H
2.2
3.7
|
L
 -42.8%
H
2.2
5.7
|
L
 -52.6%
H
2.2
12.0
|
L
 -89.7%
H
2.2
23.5
|
L
H
2.2
24.8
|
| Lexicon Pharma Inc |
|
665.2
|
1.6
|
L
 -3.1%
H
1.6
1.6
|
L
 -5.4%
H
1.6
1.8
|
L
 18.9%
H
1.3
1.8
|
L
 36.5%
H
1.1
1.8
|
L
 313.2%
H
0.3
1.8
|
L
 -30.2%
H
0.3
3.8
|
L
 -76.2%
H
0.3
6.8
|
L
 -86.6%
H
0.3
19.6
|
| Legend Biotech Corp (ADR) |
|
3,356.9
|
18.2
|
L
 -2.2%
H
17.9
18.5
|
L
 -7.2%
H
17.9
20.5
|
L
 0.2%
H
17.5
21.6
|
L
 -15.3%
H
16.2
24.1
|
L
 -52.2%
H
16.2
45.3
|
L
 -60.3%
H
16.2
77.3
|
L
 -35.9%
H
16.2
77.3
|
L
H
16.2
77.3
|
| Mustang Bio Inc |
|
6.1
|
0.8
|
L
 -6.7%
H
0.8
0.9
|
L
 -16.2%
H
0.8
1.0
|
L
 -6.7%
H
0.8
1.0
|
L
 -23.9%
H
0.5
1.2
|
L
 -41.6%
H
0.5
7
|
L
 -99.7%
H
0.1
408.5
|
L
 -100.0%
H
0.1
3045
|
L
H
0.1
10012.5
|
| Moleculin Biotech Inc |
|
10.1
|
2.1
|
L
 -5.1%
H
2.1
2.2
|
L
 4.1%
H
1.9
2.2
|
L
 -55.0%
H
1.8
5.3
|
L
 -50.5%
H
1.8
5.3
|
L
 -92.7%
H
1.8
33
|
L
 -99.4%
H
1.8
3318.8
|
L
 -99.9%
H
1.8
3318.8
|
L
H
1.8
21555
|
| Madrigal Pharma Inc |
|
10,125.2
|
441.4
|
L
 -0.4%
H
427.8
444.9
|
L
 2.0%
H
421.6
455
|
L
 -9.4%
H
416.2
498.1
|
L
 -19.2%
H
416.2
615
|
L
 28.9%
H
265
615
|
L
 76.1%
H
119.8
615
|
L
 274.9%
H
52.3
615
|
L
 5295.8%
H
6.6
615
|
| MediWound Ltd |
|
222.6
|
17.3
|
L
 -0.4%
H
17.2
17.5
|
L
 -0.2%
H
16.5
17.6
|
L
 -2.2%
H
16.4
18.3
|
L
 -6.8%
H
16.3
19.7
|
L
 -9.2%
H
14.1
22.5
|
L
 58.6%
H
7.1
24
|
L
 -57.1%
H
7.1
43.5
|
L
 -67.1%
H
7.1
62.3
|
| MEI Pharma Inc |
|
42.5
|
1.2
|
L
 -3.3%
H
1.2
1.2
|
L
H
1.2
1.3
|
L
 6.4%
H
1.0
1.3
|
L
 -14.6%
H
1.0
1.7
|
L
 -49.6%
H
1.0
9
|
L
 -75.6%
H
1.0
9
|
L
 -98.4%
H
1.0
78.2
|
L
 -95.0%
H
1.0
102.8
|
| Macrogenics Inc |
|
192.6
|
3.0
|
L
 -1.6%
H
3.0
3.1
|
L
 -11.7%
H
3.0
3.5
|
L
 78.2%
H
1.6
3.5
|
L
 88.2%
H
1.5
3.5
|
L
 39.0%
H
1.0
3.5
|
L
 -54.4%
H
1.0
21.9
|
L
 -90.3%
H
1.0
36.5
|
L
 -80%
H
1.0
36.5
|
| Mangoceuticals Inc |
|
5.9
|
0.4
|
L
 -10%
H
0.4
0.4
|
L
 2.9%
H
0.4
0.4
|
L
 -5.3%
H
0.3
0.7
|
L
 -70.5%
H
0.3
1.4
|
L
 -90.1%
H
0.3
5.2
|
L
H
0.1
6.2
|
L
H
0.1
6.2
|
L
H
0.1
6.2
|
| Magenta Therapeutics Inc |
|
-
|
78.9
|
L
 1.2%
H
76.3
79.4
|
L
 -9.2%
H
76.2
88.0
|
L
 60.3%
H
46.8
88.0
|
L
 90.4%
H
35.8
88.0
|
L
 300.7%
H
16.6
88.0
|
L
 540.4%
H
9.1
88.0
|
L
 -60.8%
H
5.1
227.2
|
L
H
5.1
336
|
| Mirum Pharma Inc |
|
5,494.1
|
91.1
|
L
 -5.7%
H
90.9
96.6
|
L
 0.1%
H
87.8
96.7
|
L
 -11.5%
H
84.3
109.3
|
L
 32.0%
H
69.0
109.3
|
L
 101.7%
H
36.9
109.3
|
L
 295.2%
H
21.8
109.3
|
L
 343.5%
H
12.8
109.3
|
L
H
6.5
109.3
|
| Milestone Pharma Inc |
|
149.0
|
1.8
|
L
 -1.7%
H
1.7
1.8
|
L
 -1.7%
H
1.7
1.8
|
L
 2.9%
H
1.5
1.8
|
L
 -18.6%
H
1.5
2.3
|
L
 -27.4%
H
0.6
3.1
|
L
 -47.0%
H
0.6
4.5
|
L
 -76.1%
H
0.6
9.9
|
L
H
0.6
28.0
|
| MoonLake Immunotherapeutics (Class A) |
|
1,175.6
|
16.4
|
L
 -2.3%
H
16.2
16.8
|
L
 -10.6%
H
16.2
19.3
|
L
 -6.5%
H
16.2
19.5
|
L
 17.5%
H
11.1
19.5
|
L
 -57.6%
H
6.0
62.8
|
L
 -29.2%
H
6.0
65.0
|
L
 55.9%
H
4.3
65.0
|
L
H
4.3
65.0
|
| Mannkind Corp |
|
828.8
|
2.7
|
L
 -1.5%
H
2.7
2.7
|
L
 3.1%
H
2.7
2.9
|
L
 -51.4%
H
2.5
5.7
|
L
 -54.9%
H
2.5
6.5
|
L
 -48.7%
H
2.5
6.5
|
L
 -33.9%
H
2.5
7.6
|
L
 -31.0%
H
2.5
7.6
|
L
 -70.3%
H
0.7
11.2
|
| Mind Medicine Inc |
|
1,748.7
|
17.5
|
L
 -3.0%
H
17.3
18.1
|
L
 -7.9%
H
17.3
19.0
|
L
 3.8%
H
16.5
19.6
|
L
 44.6%
H
12.3
19.6
|
L
 171.1%
H
4.7
19.6
|
L
 504.8%
H
2.4
19.6
|
L
 -57.9%
H
2.1
86.6
|
L
H
0.0
154.8
|
| Medicinova Inc |
|
70.4
|
1.4
|
L
 -2.7%
H
1.4
1.5
|
L
 1.4%
H
1.3
1.5
|
L
 -10.6%
H
1.3
1.7
|
L
 -2.7%
H
1.2
1.9
|
L
 -7.1%
H
1.1
2.0
|
L
 -26.7%
H
1.1
2.7
|
L
 -76.0%
H
1.1
6.0
|
L
 -75.7%
H
1.1
14.5
|
| TNF Pharma Inc |
|
35.3
|
4.5
|
L
 11.9%
H
3.9
4.6
|
L
 11.9%
H
3.7
4.6
|
L
 20.3%
H
3.4
5.0
|
L
 1.1%
H
3.4
6.3
|
L
 -88.4%
H
2.5
44.4
|
L
 -99.9%
H
2.5
7050
|
L
 -100.0%
H
2.5
29850
|
L
 -99.9%
H
2.5
29850
|
| NewAmsterdam Pharma Co NV |
|
3,384.9
|
29.4
|
L
 -3.8%
H
28.9
30.3
|
L
 -5.9%
H
28.5
31.7
|
L
 -16.5%
H
28.5
37.8
|
L
 -12.6%
H
28.5
37.8
|
L
 26.1%
H
14.1
42
|
L
 122.4%
H
5.6
42
|
L
 195.9%
H
5.6
42
|
L
H
5.6
42
|
| Neurocrine Biosciences Inc |
|
13,035.2
|
129.9
|
L
 -0.6%
H
129.0
130.9
|
L
 0.0%
H
127.2
131.9
|
L
 1.7%
H
126.0
134.8
|
L
 -8.3%
H
122.1
148.6
|
L
 16.5%
H
84.2
160.2
|
L
 37.8%
H
84.2
160.2
|
L
 39.6%
H
71.9
160.2
|
L
 284.1%
H
32.9
160.2
|
| Minerva Neurosciences Inc |
|
343.2
|
7.9
|
L
 1.0%
H
7.8
8.1
|
L
 -0.1%
H
7.1
8.8
|
L
 23.0%
H
5.0
8.8
|
L
 108.7%
H
3.8
8.8
|
L
 408.3%
H
1.2
12.5
|
L
 395.6%
H
1.2
13.5
|
L
 -68.7%
H
1.2
28.3
|
L
 -82.0%
H
1.2
126.7
|
| Nektar Therapeutics |
|
2,082.0
|
74.4
|
L
 -0.9%
H
74.1
75.6
|
L
 3.3%
H
68.9
77
|
L
 0.8%
H
62.5
77
|
L
 63.8%
H
33.4
77
|
L
 445.5%
H
6.5
77
|
L
 406.2%
H
6.2
77
|
L
 -78.5%
H
6.2
352.5
|
L
 -59.7%
H
6.2
1670.4
|
| NLS Pharmaceutics Ltd |
|
12.4
|
2.7
|
L
 1.1%
H
2.7
2.7
|
L
 3.8%
H
2.5
2.9
|
L
 0.4%
H
2.5
3.1
|
L
 1.9%
H
1.9
3.3
|
L
 -82.5%
H
1.9
30.8
|
L
 -99.5%
H
1.2
640
|
L
 -99.9%
H
1.2
1840
|
L
H
1.2
2940
|
| Nurix Therapeutics Inc |
|
1,544.7
|
15.0
|
L
 -3.0%
H
14.9
15.5
|
L
 -5.5%
H
14.6
16.1
|
L
 -4.0%
H
14.6
16.5
|
L
 -17.5%
H
14.6
20.2
|
L
 7.8%
H
8.2
22.5
|
L
 66.7%
H
4.2
29.6
|
L
 -67.3%
H
4.2
45.0
|
L
H
4.2
52.4
|
| NeuroSense Therapeutics Ltd |
|
27.1
|
0.8
|
L
 -1.2%
H
0.8
0.8
|
L
 -6.9%
H
0.8
1.1
|
L
 -19%
H
0.8
1.1
|
L
 -2.4%
H
0.7
1.1
|
L
 -31.4%
H
0.7
2.6
|
L
 -55.2%
H
0.4
2.6
|
L
H
0.4
8.2
|
L
H
0.4
8.2
|
| NRX Pharma Inc |
|
59.3
|
1.9
|
L
 -4.6%
H
1.9
2.0
|
L
 2.8%
H
1.8
2.2
|
L
 3.3%
H
1.6
2.2
|
L
 -18.4%
H
1.6
2.8
|
L
 -9.3%
H
1.6
3.8
|
L
 -73.8%
H
1.1
54
|
L
 -99.4%
H
1.1
570
|
L
H
1.1
769.9
|
| Nuvectis Pharma Inc |
|
219.9
|
8.3
|
L
 -4.7%
H
8.2
8.7
|
L
 -14.0%
H
8.2
9.7
|
L
 -7.0%
H
8.2
9.9
|
L
 9.5%
H
7.2
9.9
|
L
 -12.5%
H
5.6
11.5
|
L
 -30.5%
H
4.4
18.7
|
L
H
3.1
20.9
|
L
H
3.1
20.9
|
| Nextcure Inc |
|
43.9
|
12.3
|
L
H
12.0
12.5
|
L
 -3.1%
H
11.8
14.4
|
L
 -6.7%
H
10.6
14.7
|
L
 17.2%
H
10.4
14.7
|
L
 60.2%
H
2.8
15.7
|
L
 -35.8%
H
2.8
30.8
|
L
 -91.7%
H
2.8
149.5
|
L
H
2.8
1308
|
| Ocugen Inc |
|
760.7
|
2.3
|
L
 -5.3%
H
2.3
2.6
|
L
 31.1%
H
1.8
2.7
|
L
 61.1%
H
1.4
2.7
|
L
 64.5%
H
1.3
2.7
|
L
 307.0%
H
0.5
2.7
|
L
 139.2%
H
0.3
2.7
|
L
 -75.7%
H
0.3
17.7
|
L
 -98.3%
H
0.2
268.2
|
| Oculis Holding AG |
|
1,543.0
|
26.6
|
L
 -1.2%
H
26.3
27.1
|
L
 -7.1%
H
25.0
29.2
|
L
 -7.5%
H
25.0
30.7
|
L
 37.0%
H
19.4
30.7
|
L
 41.3%
H
14
30.7
|
L
 231.8%
H
6.3
30.7
|
L
H
6.3
30.7
|
L
H
6.3
30.7
|
| Ocular Therapeutix Inc |
|
1,848.2
|
8.5
|
L
 -2.2%
H
8.4
8.7
|
L
 -14.0%
H
8.4
9.9
|
L
 21.5%
H
6.8
11.5
|
L
 -38.1%
H
6.2
13.9
|
L
 6.9%
H
5.8
16.4
|
L
 71.2%
H
2
16.4
|
L
 -58.1%
H
2
21.2
|
L
 -3.4%
H
2
24.3
|
| Opus Genetics Inc |
|
327.1
|
4.7
|
L
 -2.5%
H
4.6
4.8
|
L
 -3.5%
H
4.6
5.3
|
L
 20.3%
H
3.3
5.3
|
L
 131.7%
H
1.9
5.3
|
L
 397.9%
H
0.7
5.3
|
L
 24.1%
H
0.7
6.6
|
L
 -37.8%
H
0.7
7.7
|
L
 -96.9%
H
0.7
340.8
|
| Olema Pharma Inc |
|
1,152.7
|
14.4
|
L
 -4.5%
H
14.3
15.5
|
L
 -8.8%
H
14.3
16.8
|
L
 -36.4%
H
13.0
25.3
|
L
 -55.9%
H
13.0
33.1
|
L
 223.2%
H
2.9
36.3
|
L
 296.1%
H
2.9
36.3
|
L
 -71.0%
H
2
49.5
|
L
H
2
60.3
|
| Omeros Corp |
|
769.3
|
10.9
|
L
 -3.7%
H
10.8
11.2
|
L
 -7.3%
H
10.8
12.0
|
L
 -9.1%
H
10.8
12.2
|
L
 22.9%
H
8.6
17.7
|
L
 27.4%
H
3.0
17.7
|
L
 206.5%
H
0.9
17.7
|
L
 -45.4%
H
0.9
20.5
|
L
 -26.2%
H
0.9
27.1
|
| ORIC Pharma Inc |
|
1,265.7
|
11.3
|
L
 -6.4%
H
11.2
11.9
|
L
 -10.3%
H
11.2
12.8
|
L
 12.0%
H
10.1
14.3
|
L
 37.5%
H
7.8
14.3
|
L
 42.9%
H
3.9
14.9
|
L
 147.8%
H
3.9
16.7
|
L
 -60.8%
H
2.4
29.3
|
L
H
2.4
40.8
|
| Oramed Pharma Inc |
|
142.5
|
3.6
|
L
 -0.8%
H
3.6
3.6
|
L
 7.5%
H
3.3
3.7
|
L
 11.9%
H
3.1
3.8
|
L
 18.2%
H
2.8
3.8
|
L
 51.1%
H
1.8
3.8
|
L
 60.5%
H
1.7
5.3
|
L
 -63.6%
H
1.7
31.5
|
L
 -42.4%
H
1.7
31.5
|
| Outlook Therapeutics Inc |
|
30.7
|
0.4
|
L
 -7.5%
H
0.4
0.4
|
L
 -15.9%
H
0.3
0.5
|
L
 -11.9%
H
0.3
0.5
|
L
 -83.7%
H
0.3
2.4
|
L
 -76.0%
H
0.3
3.0
|
L
 -99.9%
H
0.3
812
|
L
 -100.0%
H
0.3
1308
|
L
H
0.3
17568
|
| Ovid Therapeutics Inc |
|
169.5
|
2.4
|
L
 18.4%
H
2.3
2.5
|
L
 11.7%
H
1.9
2.5
|
L
 66.4%
H
1.4
2.5
|
L
 60.8%
H
1.3
2.5
|
L
 406.4%
H
0.2
2.5
|
L
 5.3%
H
0.2
4.1
|
L
 -45.2%
H
0.2
4.8
|
L
H
0.2
15.9
|
| Phibro Animal Health Corp (Class A) |
|
2,163.3
|
53.4
|
L
 1.6%
H
51.3
54.2
|
L
 5.8%
H
48
54.2
|
L
 2.1%
H
45.2
56.0
|
L
 31.5%
H
36.1
56.3
|
L
 144.3%
H
16.2
56.3
|
L
 267.6%
H
9.4
56.3
|
L
 112.0%
H
9.4
56.3
|
L
 117.2%
H
9.4
56.3
|
| Palisade Bio Inc |
|
285.0
|
1.9
|
L
 -4.0%
H
1.9
2.0
|
L
 -0.5%
H
1.9
2.1
|
L
 12.4%
H
1.6
2.1
|
L
 13.7%
H
1.5
2.6
|
L
 124.7%
H
0.5
2.6
|
L
 -93.3%
H
0.4
54.8
|
L
 -100.0%
H
0.4
12015
|
L
 -100.0%
H
0.4
1041300
|
| Puma biotech Inc |
|
306.8
|
6.0
|
L
 -1.8%
H
6
6.1
|
L
 -0.5%
H
5.8
6.2
|
L
 -10.7%
H
5.5
7.7
|
L
 8.1%
H
5.5
7.7
|
L
 86.1%
H
2.6
7.7
|
L
 168%
H
2.1
7.7
|
L
 -45.2%
H
1.6
12.0
|
L
 -84.1%
H
1.6
136.9
|
| Pacira BioSciences Inc |
|
875.4
|
21.6
|
L
 -1.5%
H
21.2
21.9
|
L
 -3.7%
H
21.2
24.1
|
L
 -4.9%
H
20.6
24.1
|
L
 -18.6%
H
18.8
27.0
|
L
 -7.3%
H
18.8
27.6
|
L
 -45.3%
H
11.2
48.6
|
L
 -69.4%
H
11.2
82.2
|
L
 -52.3%
H
11.2
82.2
|
| Processa Pharma Inc |
|
6.9
|
3.1
|
L
 -3.2%
H
3.1
3.1
|
L
 4.8%
H
2.6
3.3
|
L
 40.4%
H
1.8
3.3
|
L
 -54.2%
H
1.8
4.9
|
L
 -72.7%
H
1.8
19.6
|
L
 -98.6%
H
1.8
450
|
L
 -99.9%
H
1.8
7120
|
L
 -99.9%
H
1.8
17937.5
|
| PDS biotech Corp |
|
35.6
|
0.7
|
L
 -5.8%
H
0.6
0.7
|
L
 -5.8%
H
0.6
0.7
|
L
 -4.4%
H
0.6
0.7
|
L
 -25.3%
H
0.6
1.2
|
L
 -51.5%
H
0.6
1.9
|
L
 -89.6%
H
0.6
10.3
|
L
 -87.7%
H
0.6
17.9
|
L
 -99.6%
H
0.6
355.4
|
| Phathom Pharma Inc |
|
855.0
|
10.9
|
L
H
10.6
10.9
|
L
 -2.3%
H
10.0
11.2
|
L
 -15.0%
H
10.0
14.4
|
L
 -29.4%
H
10.0
18.3
|
L
 124.2%
H
2.2
18.3
|
L
 64.4%
H
2.2
19.7
|
L
 -75.1%
H
2.2
45.2
|
L
H
2.2
64.5
|
| Pharvaris NV |
|
1,696.1
|
26.1
|
L
 -3.0%
H
26
26.9
|
L
 0.9%
H
25.3
27.9
|
L
 -1.9%
H
25.0
29.0
|
L
 8.4%
H
23.6
29.0
|
L
 58.2%
H
11.5
29.8
|
L
 251.4%
H
6.3
33
|
L
 -24.1%
H
1.8
36.3
|
L
H
1.8
42.9
|
| Praxis Precision Medicines Inc |
|
8,188.1
|
294
|
L
 -3.1%
H
291
302.4
|
L
 -5.1%
H
288
318.7
|
L
 -10.4%
H
288
356
|
L
 10.6%
H
262.3
356
|
L
 655.2%
H
26.7
356
|
L
 1802.9%
H
11.9
356
|
L
 -53.9%
H
11.9
640.3
|
L
H
11.9
914.3
|
| PainReform Ltd |
|
1.9
|
2.5
|
L
 2.5%
H
2.4
2.5
|
L
 -7.1%
H
2.3
3.0
|
L
 -25.8%
H
2.3
3.6
|
L
 161.1%
H
0.6
3.7
|
L
 -14.8%
H
0.6
3.7
|
L
 -92.1%
H
0.2
158.5
|
L
 -99.3%
H
0.2
470.4
|
L
H
0.2
471
|
| ProQR Therapeutics NV |
|
177.0
|
1.7
|
L
 -5.1%
H
1.7
1.8
|
L
 -6.7%
H
1.7
1.9
|
L
 15.9%
H
1.4
2.0
|
L
 -21.5%
H
1.3
2.3
|
L
 -1.2%
H
1.1
3.1
|
L
 -48.3%
H
1.1
4.6
|
L
 -67.8%
H
0.5
9.5
|
L
 -59.1%
H
0.5
24
|
| Plus Therapeutics Inc |
|
42.8
|
0.2
|
L
 -4%
H
0.2
0.3
|
L
 -20%
H
0.2
0.3
|
L
 -14.3%
H
0.2
0.4
|
L
 -58.6%
H
0.2
0.6
|
L
 -59.3%
H
0.2
2.1
|
L
 -94.5%
H
0.2
5.1
|
L
 -99.4%
H
0.2
53.1
|
L
 -100.0%
H
0.2
40500
|
| PTC Therapeutics Inc |
|
5,507.0
|
66.5
|
L
 -1.4%
H
65.6
67.4
|
L
 -3.0%
H
62.1
68.9
|
L
 -3.8%
H
61.4
72.5
|
L
 -11.2%
H
61.4
80.2
|
L
 16.4%
H
36.0
87.5
|
L
 40.7%
H
17.5
87.5
|
L
 19.3%
H
17.5
87.5
|
L
 1109.6%
H
4.0
87.5
|
| Pulmatrix Inc |
|
7.6
|
2.1
|
L
 -1.4%
H
2.1
2.2
|
L
 -6.7%
H
2.1
2.3
|
L
 -14.1%
H
1.6
3.4
|
L
 -48.6%
H
1.6
4.1
|
L
 -75.2%
H
1.6
9.4
|
L
 -33.1%
H
1.6
10.4
|
L
 -93.2%
H
1.6
31.8
|
L
 -99.6%
H
1.6
1396
|
| Polypid Ltd |
|
84.2
|
4.4
|
L
 -3.3%
H
4.4
4.6
|
L
 2.1%
H
4.1
4.7
|
L
H
4.0
4.7
|
L
 12.2%
H
3.9
5.1
|
L
 43.7%
H
2.3
5.1
|
L
 -73.8%
H
2.3
17.3
|
L
 -98.6%
H
2.3
314.4
|
L
H
2.3
583.5
|
| Pyxis Oncology Inc |
|
95.9
|
1.5
|
L
 -4.9%
H
1.5
1.7
|
L
 -0.7%
H
1.5
1.7
|
L
 15.8%
H
1.3
1.7
|
L
 -54.3%
H
1.0
2.2
|
L
 32.8%
H
0.8
5.6
|
L
 -44.2%
H
0.8
6.9
|
L
H
0.8
19
|
L
H
0.8
19
|
| Pharming Grp N.V. (ADR) |
|
1,061.1
|
15.2
|
L
 -1.7%
H
15.2
15.6
|
L
 -8.6%
H
14.5
16.1
|
L
 -6.6%
H
14.5
17.4
|
L
 -8.3%
H
14.5
21.3
|
L
 73.1%
H
7.5
21.3
|
L
 41.4%
H
6.7
21.3
|
L
 11.8%
H
6.1
21.3
|
L
H
6.1
22.0
|
| Purple Biotech Ltd (ADR) |
|
3.6
|
4.0
|
L
 -1%
H
3.9
4.2
|
L
 -6.4%
H
3.7
4.3
|
L
 -32.5%
H
3.7
6.0
|
L
 -47.0%
H
3.7
7.4
|
L
 -85.9%
H
3.7
30.5
|
L
 -100.0%
H
3.7
8640
|
L
 -100.0%
H
3.7
27000
|
L
 -100.0%
H
3.7
278000
|
| Qilian Intl Holding Grp ltd (Class A) |
|
176.5
|
0.9
|
L
 -2.2%
H
0.9
1.0
|
L
 -12%
H
0.9
1.0
|
L
 -16.2%
H
0.9
1.2
|
L
 -82.4%
H
0.9
5.0
|
L
 -91.4%
H
0.9
17.2
|
L
 -88.8%
H
0.9
17.2
|
L
 -96.6%
H
0.9
27.8
|
L
H
0.9
110
|
| Quoin Pharma Ltd (ADR) |
|
12.9
|
8
|
L
 -1.7%
H
7.9
8.2
|
L
 -6.9%
H
7.8
8.9
|
L
 -10.7%
H
7.8
10.0
|
L
 -45.2%
H
7
14.7
|
L
 -96.3%
H
5.1
294
|
L
 -99.8%
H
5.1
8400
|
L
 -100.0%
H
5.1
3003840
|
L
H
5.1
3003840
|
| Ultragenyx Pharmaceutical Inc |
|
2,005.1
|
20.8
|
L
 -3.9%
H
20.6
21.5
|
L
 -9.2%
H
20.6
22.8
|
L
 2.8%
H
19.6
23.8
|
L
 -37.5%
H
18.4
35.1
|
L
 -47.7%
H
18.4
42.4
|
L
 -46.1%
H
18.4
60.4
|
L
 -83.9%
H
18.4
127.3
|
L
 -61.8%
H
18.4
179.7
|
| Regeneron Pharma |
|
79,305.7
|
750.2
|
L
 -1.2%
H
734.6
757.6
|
L
 -2.8%
H
734.6
783.1
|
L
 -5.5%
H
734.6
797
|
L
 0.1%
H
718.4
821.1
|
L
 10.6%
H
476.5
821.1
|
L
 0.3%
H
476.5
1211.2
|
L
 51.2%
H
451.6
1211.2
|
L
 105.3%
H
271.4
1211.2
|
| Regencell Bioscience Holdings Ltd |
|
12,688.6
|
25.7
|
L
 11.7%
H
22.6
29.5
|
L
 4.7%
H
22.3
29.5
|
L
 -18.7%
H
20
34.4
|
L
 52.7%
H
16.9
69
|
L
 5136.7%
H
0.5
83.6
|
L
 3514.1%
H
0.1
83.6
|
L
H
0.1
83.6
|
L
H
0.1
83.6
|
| Repligen Corp |
|
6,609.9
|
117.3
|
L
 -1.6%
H
116.2
118.9
|
L
 -3.7%
H
112.5
123.0
|
L
 -13.3%
H
112.5
140.5
|
L
 -25.2%
H
112.5
175.8
|
L
 -23.2%
H
103.0
175.8
|
L
 -31.1%
H
103.0
211.1
|
L
 -40.4%
H
103.0
327.3
|
L
 378.0%
H
21.1
327.3
|
| Regenxbio Inc |
|
424.8
|
8.2
|
L
 -4.8%
H
8.2
8.6
|
L
 -16.9%
H
8.2
9.8
|
L
 2.4%
H
7.6
10.8
|
L
 -37.5%
H
7.6
16.2
|
L
 17.6%
H
5.0
16.2
|
L
 -59.1%
H
5.0
28.8
|
L
 -80.0%
H
5.0
46.5
|
L
 -31.2%
H
5.0
85.1
|
| Rigel Pharma |
|
473.7
|
25.6
|
L
 -2.8%
H
25.5
26.3
|
L
 -9.9%
H
25.5
28.6
|
L
 -27.9%
H
25.5
37.0
|
L
 -38.9%
H
25.5
49.1
|
L
 21.9%
H
15.5
52.2
|
L
 1656.2%
H
0.7
52.2
|
L
 528.4%
H
0.6
52.2
|
L
 1221.6%
H
0.6
52.2
|
| Relmada Therapeutics Inc |
|
473.7
|
6.5
|
L
 0.2%
H
6.3
6.5
|
L
 -2.4%
H
5.8
6.7
|
L
 77.5%
H
3.7
7.5
|
L
 61.1%
H
3.2
7.5
|
L
 2053.3%
H
0.2
7.5
|
L
 161.5%
H
0.2
7.5
|
L
 -82.4%
H
0.2
40
|
L
 16.2%
H
0.2
54
|
| RenovoRx Inc |
|
35.9
|
1.0
|
L
 1.0%
H
1.0
1.0
|
L
 19.5%
H
0.8
1.1
|
L
H
0.8
1.1
|
L
 12.6%
H
0.8
1.3
|
L
 -2%
H
0.7
1.5
|
L
 -68.6%
H
0.6
4.6
|
L
H
0.6
16.7
|
L
H
0.6
16.7
|
| Roivant Sciences Ltd |
|
19,846.4
|
27.7
|
L
 -2.0%
H
27.7
28.3
|
L
 -6.6%
H
27.7
30.3
|
L
 2.4%
H
26.7
30.3
|
L
 22.2%
H
20.8
30.3
|
L
 155.6%
H
8.7
30.3
|
L
 218.7%
H
6.6
30.3
|
L
 181.5%
H
2.5
30.3
|
L
H
2.5
30.3
|
| Royalty Pharma PLC (Class A) |
|
19,595.9
|
45.7
|
L
 -0.8%
H
45.5
46.1
|
L
 -0.5%
H
45.3
46.8
|
L
 0.7%
H
44.7
47.9
|
L
 19.4%
H
38.2
47.9
|
L
 38.5%
H
29.7
47.9
|
L
 32.0%
H
24.1
47.9
|
L
 -5.9%
H
24.1
48.6
|
L
H
24.1
56.5
|
| Reviva Pharma Holdings Inc |
|
12.2
|
2.1
|
L
 -9.9%
H
2.0
2.4
|
L
 -19.9%
H
2.0
2.9
|
L
 -60.4%
H
2.0
5.4
|
L
 -83.0%
H
2.0
13.4
|
L
 -90.5%
H
2.0
23.4
|
L
 -97.4%
H
2.0
185
|
L
 -98.7%
H
2.0
190
|
L
H
2.0
302
|
| Rezolute Inc |
|
233.5
|
2.4
|
L
 -4.7%
H
2.4
2.6
|
L
 -24.0%
H
2.4
3.2
|
L
 -32.8%
H
2.4
3.8
|
L
 21.4%
H
1.8
4.1
|
L
 -30.3%
H
1.1
11.5
|
L
 34.1%
H
0.7
11.5
|
L
 -70.4%
H
0.7
17.4
|
L
 -95.1%
H
0.7
100
|
| Redhill Biopharma (ADR) |
|
4.6
|
0.9
|
L
 1.1%
H
0.9
0.9
|
L
 -1.1%
H
0.8
0.9
|
L
 -12.8%
H
0.8
1.1
|
L
 -23.9%
H
0.8
1.4
|
L
 -70.4%
H
0.8
3.3
|
L
 -99.3%
H
0.8
147.7
|
L
 -100.0%
H
0.8
11180
|
L
 -100.0%
H
0.8
16540
|
| Sunshine Biopharma Inc |
|
5.4
|
1.1
|
L
 -0.9%
H
1.1
1.2
|
L
 -7.6%
H
1.1
1.2
|
L
 -5.2%
H
1.1
1.3
|
L
 -20.9%
H
1.1
1.4
|
L
 -46.6%
H
1.1
3.9
|
L
 -98.7%
H
0.1
140
|
L
 -100.0%
H
0.1
6280
|
L
 -100.0%
H
0.1
224000
|
| Scilex Holding Co |
|
56.2
|
8.0
|
L
 -2.1%
H
7.9
8.1
|
L
 -7.6%
H
7.9
9.8
|
L
 -1.0%
H
7.7
9.8
|
L
 -48.1%
H
7.7
15.7
|
L
 2563.3%
H
0.2
34.3
|
L
 1.1%
H
0.2
34.3
|
L
 -19.7%
H
0.2
34.3
|
L
H
0.2
34.3
|
| Scynexis Inc |
|
39.8
|
0.9
|
L
 -3.3%
H
0.9
0.9
|
L
 -1.1%
H
0.9
1.0
|
L
 17.1%
H
0.7
1.0
|
L
 41.3%
H
0.6
1.0
|
L
 -19.1%
H
0.6
1.3
|
L
 -22.6%
H
0.6
3.9
|
L
 -89.7%
H
0.6
10.3
|
L
 -97.9%
H
0.6
55.1
|
| Shuttle Pharma Holdings Inc |
|
5.4
|
1.0
|
L
 -5.8%
H
1.0
1
|
L
 10.2%
H
0.9
1.1
|
L
 -10.2%
H
0.8
1.2
|
L
 -42.3%
H
0.8
4.4
|
L
 -91.4%
H
0.8
13.6
|
L
 -99.7%
H
0.8
550
|
L
H
0.8
25252
|
L
H
0.8
25252
|
| SIGA Tech Inc |
|
346.8
|
4.8
|
L
 -3.6%
H
4.8
5.0
|
L
 -14.3%
H
4.8
5.8
|
L
 -28.6%
H
4.8
6.9
|
L
 -24.1%
H
4.8
7.1
|
L
 -14.0%
H
4.8
9.6
|
L
 -11.4%
H
4.2
12.8
|
L
 -26.4%
H
4.2
27.0
|
L
 680.6%
H
0.4
27.0
|
| SILO Pharma Inc |
|
4.7
|
0.3
|
L
 3.1%
H
0.3
0.3
|
L
 -5.7%
H
0.3
0.4
|
L
 10%
H
0.2
0.4
|
L
 -17.5%
H
0.2
0.4
|
L
 -76.3%
H
0.2
1.4
|
L
 -82.6%
H
0.2
4.5
|
L
 -97.8%
H
0.2
496
|
L
 -99.3%
H
0.2
496
|
| Sol-Gel Tech Ltd |
|
217.0
|
77.9
|
L
 -2.3%
H
76.5
81.0
|
L
 -12.2%
H
72.5
96
|
L
 5.5%
H
68
98.0
|
L
 89.3%
H
38.9
98.0
|
L
 13564.9%
H
0.4
98.0
|
L
 2164.2%
H
0.3
98.0
|
L
 460.4%
H
0.3
98.0
|
L
H
0.3
98.0
|
| Soleno Therapeutics Inc |
|
1,720.6
|
33.3
|
L
 -0.9%
H
32.2
33.6
|
L
 -17.9%
H
32.2
40.4
|
L
 -13.4%
H
32.2
41.9
|
L
 -32.3%
H
32.2
50.9
|
L
 -32.8%
H
32.2
90.3
|
L
 1472.2%
H
2.0
90.3
|
L
 31.5%
H
0.9
90.3
|
L
 -67.1%
H
0.9
117.8
|
| SELLAS Life Sciences Grp Inc |
|
890.5
|
5.0
|
L
 -1.6%
H
4.8
5.1
|
L
 -14.8%
H
4.8
5.8
|
L
 35.5%
H
3.6
6.1
|
L
 135.1%
H
2.2
6.1
|
L
 338.9%
H
1.0
6.1
|
L
 267.4%
H
0.5
6.1
|
L
 -57.6%
H
0.5
15.1
|
L
 -100.0%
H
0.5
74703
|
| Soligenix Inc |
|
12.4
|
1.2
|
L
 -2.4%
H
1.2
1.3
|
L
H
1.2
1.3
|
L
 10.8%
H
1.1
1.3
|
L
H
1.0
1.5
|
L
 -47.9%
H
1.0
6.2
|
L
 -96.7%
H
1.0
85.3
|
L
 -99.7%
H
1.0
446.4
|
L
 -99.9%
H
1.0
2160
|
| Sonoma Pharma Inc |
|
4.3
|
2.5
|
L
 3.3%
H
2.4
2.6
|
L
 -5.0%
H
2.3
2.6
|
L
 -12.4%
H
2.3
3.1
|
L
 -30.1%
H
2.3
3.9
|
L
 -35.8%
H
1.8
6.9
|
L
 136.2%
H
0.1
6.9
|
L
 -67.2%
H
0.1
13.4
|
L
 -94.5%
H
0.1
74.2
|
| Synaptogenix Inc |
|
43.6
|
5.9
|
L
 -4.1%
H
5.7
6.1
|
L
 17.7%
H
4.8
6.5
|
L
 48.9%
H
3.6
6.5
|
L
 16.5%
H
3.3
6.5
|
L
 108.9%
H
1.8
12.0
|
L
 596.4%
H
0.1
12.0
|
L
 -32.0%
H
0.1
14.5
|
L
H
0.1
14.5
|
| SciSparc Ltd |
|
2.6
|
4.6
|
L
 -0.4%
H
4.4
4.6
|
L
 14.4%
H
3.6
4.8
|
L
 -11.2%
H
3.6
6.2
|
L
 -67.2%
H
3.6
14.5
|
L
 -93.4%
H
3.6
94.5
|
L
 -99.8%
H
3.6
4471.7
|
L
H
3.6
41769
|
L
H
3.6
41769
|
| ARS Pharma Inc |
|
866.9
|
8.8
|
L
 -1.4%
H
8.7
9.0
|
L
 -1.0%
H
8.2
9.1
|
L
 -6.5%
H
8.2
9.7
|
L
 -12.9%
H
8.2
13.2
|
L
 -23.3%
H
6.7
18.9
|
L
 4.3%
H
2.6
18.9
|
L
 -85.5%
H
2.6
63.4
|
L
H
2.6
63.4
|
| SeqLL Inc |
|
214.6
|
4.3
|
L
 0.9%
H
4.1
4.6
|
L
 23.7%
H
3.3
4.6
|
L
 44.6%
H
2.6
4.6
|
L
 203.6%
H
1.2
4.6
|
L
 64.6%
H
1.2
5.3
|
L
 997.4%
H
0.3
35.4
|
L
H
0.2
35.4
|
L
H
0.2
35.4
|
| Sarepta Therapeutics Inc |
|
1,784.8
|
17
|
L
 1.0%
H
16.5
17.2
|
L
 -3.7%
H
16.3
17.6
|
L
 -4.9%
H
15.5
19.3
|
L
 -19.6%
H
15.5
24.7
|
L
 -83.2%
H
10.4
81.9
|
L
 -86.1%
H
10.4
173.3
|
L
 -80.0%
H
10.4
173.3
|
L
 -0.2%
H
8
181.8
|
| Sutro Biopharma Inc |
|
353.0
|
21.5
|
L
 -6.1%
H
20.6
23.0
|
L
 -15.3%
H
20.6
26.0
|
L
 29.5%
H
16.3
26.5
|
L
 135.9%
H
8.5
26.5
|
L
 131.1%
H
5.2
26.5
|
L
 -58.7%
H
5.2
61.3
|
L
 -91.0%
H
5.2
258.9
|
L
H
5.2
283
|
| Supernus Pharma Inc |
|
2,838.2
|
49.3
|
L
 -3.0%
H
48.9
50.5
|
L
 -8.2%
H
47.7
53.4
|
L
 -4.5%
H
47.7
59.7
|
L
 1.1%
H
47.3
59.7
|
L
 53.3%
H
29.2
59.7
|
L
 41.1%
H
22
59.7
|
L
 86.3%
H
22
59.7
|
L
 254.9%
H
13.1
61.3
|
| Savara Inc |
|
1,025.5
|
5.0
|
L
 -2.1%
H
5.0
5.1
|
L
 -10.2%
H
5.0
5.7
|
L
 -12.0%
H
5.0
6.1
|
L
 -17.5%
H
5.0
6.6
|
L
 79.4%
H
1.9
7
|
L
 148.3%
H
1.6
7
|
L
 116.3%
H
1.0
7
|
L
 -69.9%
H
0.7
49.6
|
| China SXT Pharma Inc |
|
1.5
|
1.8
|
L
 -2.2%
H
1.8
1.9
|
L
 -15.4%
H
1.8
2.2
|
L
 -29.9%
H
1.8
2.7
|
L
 12.1%
H
0.0
7.0
|
L
 -32.8%
H
0.0
7.0
|
L
 -75.3%
H
0.0
9.4
|
L
 -96.7%
H
0.0
57.5
|
L
H
0.0
2335
|
| Sanofi (ADR) |
|
105,394.0
|
43.6
|
L
 -1.0%
H
43.3
43.8
|
L
 -0.8%
H
43.3
44.6
|
L
 -6.0%
H
43.3
48.8
|
L
 -9.4%
H
43.3
49.4
|
L
 -25.9%
H
43.3
59.2
|
L
 -8.6%
H
42.6
60.1
|
L
 -11.2%
H
36.9
60.1
|
L
 8.0%
H
36.8
60.1
|
| Protara Therapeutics Inc |
|
282.9
|
5.2
|
L
 -4.0%
H
5.2
5.5
|
L
 -8.4%
H
5.2
5.7
|
L
 -20.2%
H
5.2
7.5
|
L
 -2.2%
H
4.7
7.5
|
L
 18.3%
H
2.8
7.8
|
L
 50.3%
H
1.0
10.5
|
L
 -70.3%
H
1.0
18.9
|
L
 -98.1%
H
1.0
465.2
|
| Tarsus Pharma Inc |
|
2,947.1
|
69.3
|
L
 -0.8%
H
68.3
70.1
|
L
 -5.2%
H
67.1
72.1
|
L
 10.3%
H
60.9
80
|
L
 -11.0%
H
60.5
84.1
|
L
 45.8%
H
38.5
85.3
|
L
 443.1%
H
11.3
85.3
|
L
 111.0%
H
10.8
85.3
|
L
H
10.8
85.3
|
| Theravance Biopharma Inc |
|
699.8
|
13.8
|
L
 -0.8%
H
13.7
13.9
|
L
 -1.6%
H
13.5
14.1
|
L
 -26.6%
H
13.1
19.9
|
L
 -22.9%
H
13.1
21.0
|
L
 47.7%
H
7.9
21.0
|
L
 34.7%
H
7.4
21.0
|
L
 -33.2%
H
6.1
22.7
|
L
 -22.2%
H
6.1
43.4
|
| Tenax Therapeutics Inc |
|
268.5
|
15.6
|
L
 2.9%
H
15
15.7
|
L
 7.6%
H
13.6
15.7
|
L
 25.1%
H
10.4
15.7
|
L
 32.4%
H
10.4
18.4
|
L
 150.6%
H
4.6
18.4
|
L
 -62.1%
H
2.8
61.2
|
L
 -99.6%
H
2.8
3952
|
L
 -100.0%
H
2.8
94080
|
| TG Therapeutics Inc |
|
4,889.7
|
30.6
|
L
 -2.8%
H
30.3
31.3
|
L
 4.6%
H
26.8
32.5
|
L
 5.4%
H
26.8
32.5
|
L
 -1.6%
H
26.8
33.2
|
L
 -25.4%
H
25.3
46.5
|
L
 107.0%
H
6.5
46.5
|
L
 -36.5%
H
3.5
51.3
|
L
 265.8%
H
3.3
56.7
|
| Alpha Teknova Inc |
|
145.2
|
2.7
|
L
 -5.9%
H
2.7
2.9
|
L
 5.0%
H
2.5
3.1
|
L
 36.2%
H
1.9
3.1
|
L
 -42.3%
H
1.9
4.9
|
L
 -52.0%
H
1.9
7.5
|
L
 -15.6%
H
1.2
10.4
|
L
H
1.2
30.9
|
L
H
1.2
30.9
|
| Tiziana Life Sciences Ltd |
|
160.3
|
1.3
|
L
 -3.1%
H
1.3
1.3
|
L
 -8.0%
H
1.2
1.4
|
L
 -9.4%
H
1.2
1.6
|
L
 -13.7%
H
1.2
1.8
|
L
 -18.7%
H
0.7
2.6
|
L
 88.1%
H
0.4
2.6
|
L
 -60.7%
H
0.4
3.3
|
L
H
0.4
12.2
|
| Tonix Pharma Holding Corp |
|
185.8
|
14.5
|
L
 -2.9%
H
14.5
15.1
|
L
 2.5%
H
13.2
15.1
|
L
 -4.7%
H
13.1
15.5
|
L
 -19.2%
H
13.1
20.0
|
L
 -10.8%
H
13.1
70.0
|
L
 -99.9%
H
0.2
12800.1
|
L
 -100.0%
H
0.2
972800
|
L
 -100.0%
H
0.2
2412800000
|
| Tenaya Therapeutics Inc |
|
180.1
|
0.8
|
L
 -3.5%
H
0.8
0.9
|
L
 -7.8%
H
0.8
1.0
|
L
 31.8%
H
0.5
1.0
|
L
 23.9%
H
0.5
1.0
|
L
 13.7%
H
0.4
2.4
|
L
 -66.8%
H
0.4
8.1
|
L
H
0.4
32
|
L
H
0.4
32
|
| Tempest Therapeutics Inc |
|
30.7
|
2.3
|
L
 0.4%
H
2.2
2.3
|
L
 -5%
H
2.2
2.4
|
L
 -3.4%
H
2.1
2.5
|
L
 -22.2%
H
2.1
3.2
|
L
 165.1%
H
0.4
12.2
|
L
 88.4%
H
0.2
12.2
|
L
 -93.4%
H
0.2
41
|
L
 -99.9%
H
0.2
2623.5
|
| Travere Therapeutics Inc |
|
2,471.2
|
26.8
|
L
 -3.5%
H
26.7
27.6
|
L
 -6.4%
H
26.7
28.6
|
L
 -6.8%
H
26.4
31.5
|
L
 -21.0%
H
22.6
42.1
|
L
 28.4%
H
12.9
42.1
|
L
 26.4%
H
5.1
42.1
|
L
 -3.8%
H
5.1
42.1
|
L
 93.8%
H
5.1
42.1
|
| TherapeuticsMD Inc |
|
25.6
|
2.2
|
L
 -0.9%
H
2.2
2.3
|
L
 -3.9%
H
2.2
2.3
|
L
 -3.9%
H
2.1
2.4
|
L
 32.3%
H
1.6
3.0
|
L
 187.0%
H
0.7
3.0
|
L
 -36.5%
H
0.7
4.7
|
L
 -97.2%
H
0.7
83
|
L
 -99.3%
H
0.7
464.5
|
| Universe Pharma INC |
|
1.5
|
2.7
|
L
 0.8%
H
2.7
2.7
|
L
 12.2%
H
2.3
2.8
|
L
 -0.4%
H
2
3.1
|
L
 -27.5%
H
2
7.2
|
L
 -31.9%
H
0.1
11
|
L
 -69.8%
H
0.1
64.8
|
L
H
0.1
179.9
|
L
H
0.1
179.9
|
| United Therapeutics Corp |
|
23,123.5
|
527.6
|
L
 -2.3%
H
523.5
540.6
|
L
 -1.5%
H
523.5
545.5
|
L
 9.4%
H
466
548.1
|
L
 3.3%
H
455.6
548.1
|
L
 63.4%
H
267.0
548.1
|
L
 140.1%
H
204.4
548.1
|
L
 208.2%
H
158.4
548.1
|
L
 347.0%
H
74.3
548.1
|
| Vericel Corp |
|
1,622.4
|
32.0
|
L
 -1.7%
H
31.9
32.4
|
L
 -4.3%
H
31.2
33.5
|
L
 -13.2%
H
31.2
39.0
|
L
 -12.2%
H
31.2
41.7
|
L
 -32.9%
H
29.2
48.7
|
L
 9.0%
H
28.0
63
|
L
 -31.7%
H
17.3
68.9
|
L
 626.4%
H
2.0
68.9
|
| Veru Inc |
|
37.1
|
2.3
|
L
 -4.2%
H
2.3
2.4
|
L
 -6.5%
H
2.3
2.6
|
L
 -1.7%
H
2.3
2.7
|
L
 3.6%
H
2.1
2.8
|
L
 -53.4%
H
2.1
7.4
|
L
 -85.6%
H
2.1
19.2
|
L
 -98.5%
H
2.1
245.5
|
L
 -89.1%
H
2.1
245.7
|
| Dogwood Therapeutics Inc |
|
104.2
|
3.1
|
L
 -2.8%
H
2.9
3.4
|
L
 1.0%
H
2.8
3.4
|
L
 4.3%
H
2.7
3.5
|
L
 -51.7%
H
2.6
6.8
|
L
 -48.6%
H
2.6
9.5
|
L
 909.7%
H
0.1
29.3
|
L
 -49.2%
H
0.1
29.3
|
L
H
0.1
29.3
|
| Viking Therapeutics Inc |
|
3,879.2
|
33.6
|
L
 -5.5%
H
33.3
35.4
|
L
 -3.1%
H
33.3
37.5
|
L
 10.3%
H
29.7
37.5
|
L
 -2.1%
H
25.8
37.8
|
L
 12.5%
H
18.9
43.2
|
L
 183.8%
H
8.3
99.4
|
L
 411.7%
H
2.0
99.4
|
L
 1786.0%
H
0.9
99.4
|
| Vanda Pharma Inc |
|
507.7
|
8.6
|
L
 -0.1%
H
8.5
9.1
|
L
 -10.2%
H
8.4
9.7
|
L
 38.6%
H
5.7
9.9
|
L
 26.0%
H
5.7
9.9
|
L
 69.1%
H
3.8
9.9
|
L
 31.7%
H
3.3
9.9
|
L
 -51.0%
H
3.3
21.9
|
L
 16.7%
H
3.3
33.4
|
| Verrica Pharma Inc |
|
105.8
|
6.2
|
L
 -2.4%
H
6.1
6.4
|
L
 3.0%
H
5.1
6.6
|
L
 11.8%
H
5
6.6
|
L
 -23.5%
H
5
9.0
|
L
 847.7%
H
0.4
9.8
|
L
 -12.3%
H
0.4
11.4
|
L
 -64.4%
H
0.4
17.4
|
L
H
0.4
23.3
|
| Viridian Therapeutics Inc |
|
2,830.1
|
27.7
|
L
 -3.2%
H
27
28.5
|
L
 -5.1%
H
27
29.9
|
L
 -2.1%
H
26.3
30.8
|
L
 -13.8%
H
26.3
34.3
|
L
 72.6%
H
9.9
34.3
|
L
 0.9%
H
9.9
34.3
|
L
 51.4%
H
9.5
39
|
L
 -76.3%
H
4.7
270
|
| Vertex Pharma |
|
115,910.7
|
456.3
|
L
 -1.3%
H
453.5
464.0
|
L
 -8.6%
H
453.5
499.5
|
L
 -4.4%
H
450.7
507.9
|
L
 1.5%
H
429
507.9
|
L
 -11.2%
H
362.5
516.5
|
L
 54.3%
H
296.1
519.9
|
L
 110.2%
H
176.4
519.9
|
L
 476.3%
H
71.5
519.9
|
| Viatris |
|
15,866.2
|
13.8
|
L
 -0.1%
H
13.7
13.8
|
L
 -2.1%
H
13.4
14.3
|
L
 -12.5%
H
13.4
16.5
|
L
 17.8%
H
11.6
16.5
|
L
 49.0%
H
6.9
16.5
|
L
 46.1%
H
6.9
16.5
|
L
 -8.6%
H
6.9
16.5
|
L
 -68.8%
H
6.9
50.4
|
| vTv Therapeutics Inc (Class A) |
|
141.3
|
35.9
|
L
 -2.3%
H
34.9
36.7
|
L
 2.4%
H
31.2
39.4
|
L
 -2.8%
H
31.2
41.7
|
L
 4.2%
H
28.8
44
|
L
 57.7%
H
14
44
|
L
 4498.7%
H
0.4
44
|
L
 1145.5%
H
0.4
44
|
L
 504.9%
H
0.4
44
|
| VYNE Therapeutics Inc |
|
20.0
|
0.6
|
L
 -1.6%
H
0.6
0.6
|
L
H
0.6
0.6
|
L
 1.7%
H
0.6
0.6
|
L
H
0.6
0.6
|
L
 -67.9%
H
0.3
2.0
|
L
 -76%
H
0.3
8.7
|
L
 -99.6%
H
0.3
141.5
|
L
H
0.3
2869.9
|
| Vaccitech PLC (ADR) |
|
26.2
|
0.7
|
L
H
0.7
0.7
|
L
 21.4%
H
0.6
0.7
|
L
 11.5%
H
0.6
0.7
|
L
 -5.6%
H
0.6
0.8
|
L
 -27.7%
H
0.6
2.9
|
L
 -77.3%
H
0.6
5.1
|
L
H
0.6
18.0
|
L
H
0.6
18.0
|
| Xenetic Biosciences Inc |
|
6.7
|
2.9
|
L
 -6.1%
H
2.9
3.1
|
L
 11.0%
H
2.5
3.5
|
L
 34.4%
H
2.2
3.5
|
L
 45.1%
H
2.0
3.5
|
L
 -20.2%
H
1.9
13.9
|
L
 -31.9%
H
1.9
13.9
|
L
 -88.6%
H
1.9
56.8
|
L
 -99.8%
H
1.9
1227.6
|
| Xenon Pharma Inc |
|
5,140.7
|
53.9
|
L
 -2.4%
H
53.7
54.9
|
L
 -11.1%
H
53.7
61.4
|
L
 29.3%
H
41.1
64.0
|
L
 25.3%
H
39.3
64.0
|
L
 51.3%
H
26.7
64.0
|
L
 60.4%
H
26.7
64.0
|
L
 178.0%
H
14.7
64.0
|
L
 671.8%
H
2.1
64.0
|
| Xilio Therapeutics Inc |
|
547.3
|
7.5
|
L
 0.3%
H
7.4
7.9
|
L
 -5.0%
H
6.5
8.1
|
L
 -4.5%
H
6.5
8.3
|
L
 -18.1%
H
6.5
10.4
|
L
 -34.1%
H
6.5
16.5
|
L
 -81.9%
H
6.5
51.4
|
L
H
6.5
391.3
|
L
H
6.5
391.3
|
| XOMA Corp |
|
332.6
|
28.0
|
L
 3.6%
H
27.2
30.1
|
L
 2.6%
H
25.7
30.1
|
L
 14.3%
H
23.6
30.1
|
L
 10.8%
H
22.3
30.8
|
L
 35.0%
H
18.4
39.9
|
L
 40.4%
H
13.5
39.9
|
L
 -28.1%
H
13.5
42.0
|
L
 72.8%
H
4.0
46.3
|
| XORTX Therapeutics Inc |
|
2.8
|
0.4
|
L
 2.6%
H
0.4
0.4
|
L
 -14.9%
H
0.4
0.5
|
L
 -7.0%
H
0.4
0.5
|
L
 -31.0%
H
0.4
0.6
|
L
 -58.8%
H
0.4
1.4
|
L
 -20%
H
0.3
7
|
L
 -82.8%
H
0.3
8.2
|
L
H
0.3
8.2
|
| Zevra Therapeutics Inc |
|
542.1
|
9.6
|
L
 -2.7%
H
9.6
9.9
|
L
 -12.9%
H
9.5
10.9
|
L
 12.1%
H
8.4
11.4
|
L
 18.7%
H
8.0
11.4
|
L
 15.3%
H
6.2
13.2
|
L
 100.6%
H
3.9
13.2
|
L
 -15.7%
H
3.9
15.7
|
L
 -95.5%
H
1.9
316
|
| Zymeworks BC Inc |
|
1,758.7
|
23.7
|
L
 -1.5%
H
23.4
24
|
L
 -7.0%
H
22.4
26.1
|
L
 2.6%
H
21.9
28
|
L
 -7.5%
H
21.9
28
|
L
 88.2%
H
9.0
28.5
|
L
 183.1%
H
6.0
28.5
|
L
 -28.2%
H
4.1
39.4
|
L
H
4.1
59.0
|
| Sagimet Biosciences Inc (Class A) |
|
160.3
|
4.9
|
L
 -5.2%
H
4.9
5.2
|
L
 -11.0%
H
4.9
6
|
L
 -4.5%
H
4.9
6.3
|
L
 -21.5%
H
4.9
7.2
|
L
 30.2%
H
1.7
11.4
|
L
 -35.4%
H
1.7
20.7
|
L
 -35.4%
H
1.7
20.7
|
L
 -35.4%
H
1.7
20.7
|
| CervoMed Inc |
|
39.3
|
4.3
|
L
 -6.2%
H
4.1
4.6
|
L
 -12.6%
H
4.0
5.0
|
L
 -6.4%
H
3.6
5.2
|
L
 -46.8%
H
3.6
8.6
|
L
 -53.0%
H
3.6
16.9
|
L
 -53.2%
H
1.8
26.4
|
L
 -94.8%
H
1.8
84
|
L
 -100.0%
H
1.8
17437.5
|
| Dianthus Therapeutics Inc |
|
3,406.8
|
78.8
|
L
 -0.1%
H
77.8
80.5
|
L
 -9.3%
H
76.2
88.0
|
L
 60.2%
H
46.8
88.0
|
L
 90.3%
H
35.8
88.0
|
L
 258.8%
H
13.4
88.0
|
L
 10271.1%
H
6.6
88.0
|
L
 10271.1%
H
6.6
88.0
|
L
 10271.1%
H
6.6
88.0
|
| Neumora Therapeutics Inc |
|
465.6
|
2.7
|
L
 -3.2%
H
2.7
2.8
|
L
 -16.0%
H
2.7
3.4
|
L
 -22.6%
H
2.7
3.7
|
L
 54.8%
H
1.5
3.7
|
L
 130.3%
H
0.6
3.7
|
L
H
0.6
21
|
L
H
0.6
21
|
L
H
0.6
21
|
| Agape ATP Corp |
|
2.8
|
2.8
|
L
 3.4%
H
2.5
3.2
|
L
 -27.3%
H
2.5
6.3
|
L
 35.5%
H
1.7
6.3
|
L
 -61.0%
H
1.7
7.3
|
L
 -94.6%
H
1.7
128.3
|
L
 -99.8%
H
1.7
1590
|
L
 -99.8%
H
1.7
1590
|
L
 -99.8%
H
1.7
1590
|
| Barinthus Biotherapeutics PLC. (ADR) |
|
27.8
|
0.7
|
L
H
0.7
0.7
|
L
 21.4%
H
0.6
0.7
|
L
 11.5%
H
0.6
0.7
|
L
 -5.6%
H
0.6
0.8
|
L
 -34.6%
H
0.6
2.9
|
L
 -81.3%
H
0.6
5.1
|
L
 -81.3%
H
0.6
5.1
|
L
 -81.3%
H
0.6
5.1
|
| Viamet Pharma Corp |
|
1,139.8
|
10.8
|
L
 -2.8%
H
10.5
11.2
|
L
 -1.5%
H
10.4
11.8
|
L
 3.0%
H
10
12.1
|
L
 3.0%
H
10
12.1
|
L
 3.0%
H
10
12.1
|
L
 3.0%
H
10
12.1
|
L
 3.0%
H
10
12.1
|
L
 3.0%
H
10
12.1
|
| Onconetix Inc |
|
0.8
|
0.5
|
L
 -1.9%
H
0.5
0.5
|
L
 -12.1%
H
0.5
0.6
|
L
 -34.6%
H
0.4
1.0
|
L
 -73.3%
H
0.4
2.3
|
L
 292.3%
H
0.1
5.9
|
L
 -98.8%
H
0.1
63.2
|
L
 -72.0%
H
0.1
3636
|
L
 -72.0%
H
0.1
3636
|
| Talphera Inc |
|
36.4
|
0.8
|
L
 -7.1%
H
0.8
0.9
|
L
 -12.4%
H
0.8
0.9
|
L
 -1.3%
H
0.8
1
|
L
 -30.4%
H
0.8
1.3
|
L
 36.8%
H
0.4
1.6
|
L
H
0.4
1.6
|
L
H
0.4
1.6
|
L
H
0.4
1.6
|
| ArriVent BioPharma Inc |
|
1,015.8
|
23.0
|
L
 -4.3%
H
22.9
24.8
|
L
 -9.3%
H
22.9
26.0
|
L
 0.9%
H
21.9
27.2
|
L
 3.3%
H
18.2
27.2
|
L
 11.8%
H
15.5
27.2
|
L
H
14.4
36.2
|
L
H
14.4
36.2
|
L
H
14.4
36.2
|
| Skye Bioscience Inc |
|
21.2
|
0.7
|
L
 -1.5%
H
0.7
0.7
|
L
 -17.5%
H
0.6
0.7
|
L
 -10.8%
H
0.6
0.8
|
L
 -37.7%
H
0.6
1.2
|
L
 -73.9%
H
0.6
5.8
|
L
H
0.6
7.2
|
L
H
0.6
7.2
|
L
H
0.6
7.2
|
| Actuate Therapeutics Inc |
|
58.1
|
2.5
|
L
 -9.8%
H
2.5
2.7
|
L
 -12.0%
H
2.3
3.1
|
L
 -41.3%
H
2.3
4.5
|
L
 -63.6%
H
2.3
7.3
|
L
 -66.2%
H
2.3
12.0
|
L
H
2.3
12.0
|
L
H
2.3
12.0
|
L
H
2.3
12.0
|
| Bicara Therapeutics Inc |
|
1,203.3
|
18.6
|
L
 -3.9%
H
18.5
19.2
|
L
 -7.4%
H
18.4
20.3
|
L
 31.9%
H
13.9
20.3
|
L
 3.3%
H
13.8
20.3
|
L
 37.6%
H
7.8
20.3
|
L
H
7.8
28.1
|
L
H
7.8
28.1
|
L
H
7.8
28.1
|
| Gelteq Ltd |
|
7.9
|
0.7
|
L
 -6.3%
H
0.7
0.8
|
L
H
0.6
0.8
|
L
 -7.5%
H
0.6
0.8
|
L
 -16.9%
H
0.6
1.4
|
L
 -39.3%
H
0.6
4.1
|
L
H
0.6
5.5
|
L
H
0.6
5.5
|
L
H
0.6
5.5
|
| Septerna Inc |
|
1,107.4
|
24.7
|
L
 -2.0%
H
24.5
25.4
|
L
 -12.0%
H
24.1
28
|
L
 -18.6%
H
24.1
32.6
|
L
 -7.1%
H
23.0
32.6
|
L
 289.0%
H
4.7
32.6
|
L
H
4.2
32.6
|
L
H
4.2
32.6
|
L
H
4.2
32.6
|
| Alpha Cognition Inc |
|
128.1
|
5.9
|
L
 2.3%
H
5.7
5.9
|
L
H
5.7
6.1
|
L
 13.1%
H
5.2
6.5
|
L
 10.1%
H
4.5
6.9
|
L
 3.5%
H
3.8
11.5
|
L
H
3.8
11.5
|
L
H
3.8
11.5
|
L
H
3.8
11.5
|
| Atlantic Intl Corp |
|
317.6
|
4.5
|
L
 4.4%
H
4.1
4.5
|
L
 29.2%
H
3.3
4.6
|
L
 51.0%
H
2.6
4.6
|
L
 217.0%
H
1.2
4.6
|
L
 71.9%
H
1.2
5.3
|
L
 71.9%
H
1.2
5.3
|
L
 71.9%
H
1.2
5.3
|
L
 71.9%
H
1.2
5.3
|
| BeiGene Ltd (ADR) |
|
31,414.6
|
283.2
|
L
 -1.5%
H
281.0
286.9
|
L
 -7.3%
H
281.0
302.1
|
L
 -20.2%
H
281.0
372.7
|
L
 -7.5%
H
281.0
372.7
|
L
 6.8%
H
196.5
385.2
|
L
 53.3%
H
172.7
385.2
|
L
 53.3%
H
172.7
385.2
|
L
 53.3%
H
172.7
385.2
|
| Jupiter Neurosciences Inc |
|
13.8
|
0.4
|
L
 2.6%
H
0.4
0.4
|
L
 -2.4%
H
0.3
0.4
|
L
 -28.6%
H
0.3
0.6
|
L
 -64.6%
H
0.3
1.2
|
L
 -31.0%
H
0.3
3.3
|
L
 -31.0%
H
0.3
3.3
|
L
 -31.0%
H
0.3
3.3
|
L
 -31.0%
H
0.3
3.3
|
| Ascentage Pharma Grp Intl (ADR) |
|
2,233.0
|
24.0
|
L
 -1.6%
H
24.0
24.0
|
L
 -1.9%
H
22.7
25
|
L
 -3.9%
H
21.2
25.5
|
L
 -15.8%
H
21.2
29.5
|
L
 22.1%
H
17.6
48.5
|
L
 38.2%
H
17
48.5
|
L
 38.2%
H
17
48.5
|
L
 38.2%
H
17
48.5
|
| Maze Therapeutics Inc |
|
2,397.3
|
49.8
|
L
 -1.1%
H
49.2
51.7
|
L
 -2.4%
H
47
53.7
|
L
 6.1%
H
42.6
53.7
|
L
 29.7%
H
37.4
53.7
|
L
 333.6%
H
6.7
53.7
|
L
H
6.7
53.7
|
L
H
6.7
53.7
|
L
H
6.7
53.7
|
| Aardvark Therapeutics Inc |
|
110.4
|
5.1
|
L
 -4.9%
H
5.0
5.5
|
L
 -12.4%
H
4.8
5.9
|
L
 -59.3%
H
4.7
13
|
L
 -61.7%
H
4.7
16.6
|
L
 -45.3%
H
4.7
17.9
|
L
H
4.7
19.6
|
L
H
4.7
19.6
|
L
H
4.7
19.6
|
| Cuprina Holdings (Cayman) Ltd (Class A) |
|
7.3
|
0.3
|
L
H
0.3
0.4
|
L
 -8.1%
H
0.3
0.4
|
L
 -22.7%
H
0.3
0.4
|
L
 -32%
H
0.3
0.5
|
L
H
0.3
9.5
|
L
H
0.3
9.5
|
L
H
0.3
9.5
|
L
H
0.3
9.5
|
| Jyong Biotech Ltd |
|
133.6
|
1.8
|
L
H
1.8
1.9
|
L
 -26.2%
H
1.8
2.6
|
L
 5.3%
H
1.7
3.1
|
L
 -38.4%
H
1.4
7.8
|
L
 -82.2%
H
1.4
67
|
L
 -82.2%
H
1.4
67
|
L
 -82.2%
H
1.4
67
|
L
 -82.2%
H
1.4
67
|
| Black Titan Corp |
|
13.9
|
1.4
|
L
 -2.1%
H
1.4
1.4
|
L
 -7.3%
H
1.4
1.5
|
L
 -13.1%
H
1.4
1.7
|
L
 -36.8%
H
1.4
3.3
|
L
 -94.2%
H
1.4
23.5
|
L
 -94.2%
H
1.4
23.5
|
L
 -94.2%
H
1.4
23.5
|
L
 -94.2%
H
1.4
23.5
|
| MapLight Therapeutics Inc |
|
742.3
|
16.4
|
L
 -8.5%
H
16.3
17.9
|
L
 -13.8%
H
16.3
21.5
|
L
 -5.2%
H
16.3
21.5
|
L
 -16.7%
H
15.5
21.5
|
L
 -10.8%
H
12.2
21.6
|
L
 -10.8%
H
12.2
21.6
|
L
 -10.8%
H
12.2
21.6
|
L
 -10.8%
H
12.2
21.6
|
| NovaBridge Biosciences ADR |
|
324.0
|
2.8
|
L
 -2.4%
H
2.7
3.0
|
L
 -13.3%
H
2.7
3.4
|
L
 -12.7%
H
2.7
3.9
|
L
 -32.0%
H
2.7
5.2
|
L
 -38.2%
H
2.7
5.2
|
L
 -38.2%
H
2.7
5.2
|
L
 -38.2%
H
2.7
5.2
|
L
 -38.2%
H
2.7
5.2
|
| Evommune Inc |
|
751.5
|
23.8
|
L
 -4.8%
H
23.6
25.5
|
L
 -0.7%
H
20.9
25.5
|
L
 -23.6%
H
20.9
32.0
|
L
 49.8%
H
13.9
33.2
|
L
 17.8%
H
13.9
33.2
|
L
 17.8%
H
13.9
33.2
|
L
 17.8%
H
13.9
33.2
|
L
 17.8%
H
13.9
33.2
|
| Aktis Oncology Inc |
|
-
|
18.8
|
L
 -2.1%
H
18.7
19.7
|
L
 -0.8%
H
18.0
20.7
|
L
 4.9%
H
17.5
21.6
|
L
 -16.0%
H
16.8
24.5
|
L
 -16.0%
H
16.8
24.5
|
L
 -16.0%
H
16.8
24.5
|
L
 -16.0%
H
16.8
24.5
|
L
 -16.0%
H
16.8
24.5
|
| Helus Pharma Inc |
|
238.0
|
4.8
|
L
 -1.9%
H
4.7
4.9
|
L
 -16.9%
H
4.5
5.9
|
L
 -29.4%
H
4.5
8.6
|
L
 -36.7%
H
4.5
8.6
|
L
 -36.7%
H
4.5
8.6
|
L
 -36.7%
H
4.5
8.6
|
L
 -36.7%
H
4.5
8.6
|
L
 -36.7%
H
4.5
8.6
|
| NervGen Pharma Corp |
|
323.2
|
4.1
|
L
 1.0%
H
4.0
4.1
|
L
 0.7%
H
3.6
4.1
|
L
 -0.7%
H
3.6
4.5
|
L
 -29.0%
H
3.6
5.9
|
L
 -29.0%
H
3.6
5.9
|
L
 -29.0%
H
3.6
5.9
|
L
 -29.0%
H
3.6
5.9
|
L
 -29.0%
H
3.6
5.9
|
| Veradermics Inc |
|
2,125.7
|
60.6
|
L
 -0.8%
H
60.3
63.0
|
L
 19.6%
H
49.9
63.0
|
L
 27.9%
H
39.7
63.0
|
L
 60.5%
H
35.1
63.0
|
L
 60.5%
H
35.1
63.0
|
L
 60.5%
H
35.1
63.0
|
L
 60.5%
H
35.1
63.0
|
L
 60.5%
H
35.1
63.0
|
| Eikon Therapeutics Inc |
|
714.8
|
13.2
|
L
 3.1%
H
12.8
13.8
|
L
 -5.6%
H
10.8
14.6
|
L
 -15.8%
H
10.8
16.5
|
L
 -11.7%
H
10.8
16.5
|
L
 -11.7%
H
10.8
16.5
|
L
 -11.7%
H
10.8
16.5
|
L
 -11.7%
H
10.8
16.5
|
L
 -11.7%
H
10.8
16.5
|
| Satellos Bioscience Inc |
|
-
|
7.0
|
L
 -4.9%
H
6.8
7.7
|
L
 -27.2%
H
6.8
10.3
|
L
 -39.2%
H
6.8
13.4
|
L
 -38.2%
H
6.8
13.4
|
L
 -38.2%
H
6.8
13.4
|
L
 -38.2%
H
6.8
13.4
|
L
 -38.2%
H
6.8
13.4
|
L
 -38.2%
H
6.8
13.4
|